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Abstract
INDIRECT SCREENING: ENHANCING IDENTIFICATION OF ILLICIT DRUG USE
DURING PREGNANCY
By Courtney E. Smith, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2012
Major Director: Dace S. Svikis, Ph.D.
Professor
Department of Psychology
OBJECTIVE: Most drug use screening measures rely on and are validated against self-report.
Fear of negative consequences often promotes denial of drug use. For pregnant women, social
stigma and fear of legal consequences make underreporting of drug use even more likely. An
indirect screener that could effectively identify pregnant women at risk for illicit drug use
without reliance on disclosure would be clinically significant. The purpose of the current study
was to develop and validate an indirect measure of prenatal drug use by comparing correlates of
prenatal drug use to urinalysis results. METHOD: Pregnant women attending an OB
appointment at the VCUHS Women’s Health Clinic were recruited and consented to participate
in an anonymous, two-phase study. In Phase 1, women completed a 20-minute computerized
assessment which included a true/false index of items known to tap behavioral, medical,

psychological, experiential and demographic correlates of drug abuse and dependence. In Phase
2, participants were asked to provide a urine sample for drug testing. Women received a $20 gift
card after they participated in each phase. RESULTS: Two hundred and thirty-one women
completed both Phase 1 and 2 (94% completion rate). Participants were primarily AfricanAmerican (66%), single (75%) and receiving public assistance (70%). Urinalysis revealed that
16% of the sample tested positive for recent drug use, while only 5% of women self-reported
past month drug use. After examining the univariate and multivariate relationships between each
indirect item and drug status (i.e., positive or negative urinalysis), six indirect items were chosen
to comprise the Wayne Indirect Drug Use Screener-Pregnancy (WIDUS-P). Cross-validation
analyses resulted in a sensitivity of .90, specificity of .75, and AUC of .85. In comparison to
direct screening approaches, the WIDUS-P was superior in identifying pregnant women who had
used drugs recently. CONCLUSIONS: Findings support the use of an indirect screening tool to
identify prenatal drug use, especially over currently-used direct methods. Such a measure could
easily be implemented into regular clinic practice and result in more cost-effective and better
identification of prenatal drug use.

Indirect Screening: Enhancing Identification of Illicit Drug Use during Pregnancy
Statement of the Problem
Drug use is common in today’s society. A 2008 national survey found that almost onetenth of study participants reported recent use of illicit drugs (SAMSHA, 2009). Although men
used illicit drugs at a higher rate than women (9.9% versus 6.3%), the rate of drug use among
women increased from 2007 to 2008 but remained stable for men. During pregnancy, the
majority of drug-using women tend to abstain from substance use (SAMHSA, 2009; Ebrahim &
Gfroerer, 2003), however a proportion of drug-using women continue to use during the prenatal
period (Bailey, Hill, Hawkins, Catalano, & Abbott, 2008). This rate, which ranges from 5-14%
depending on the study, is significant given the numerous negative consequences associated with
prenatal drug use for both mother and offspring (SAMSHA, 2009; Chasnoff, Landress, &
Barrett, 1990; Huestis & Choo, 2002). Unfortunately, current prevalence rates of prenatal drug
use are likely underestimations because drug use is frequently underreported (Magura & Kang,
1996). Women face social stigma and negative consequences (e.g., loss of custody, legal
charges) when they report prenatal drug use so it is not surprising that they minimize or deny
using (Ondersma, Malcoe, & Simpson, 2000; Ondersma, Simpson, Brestan, & Ward, 2001;
Lester, El Sohly, Wright, Smerigilio, Verter, Bauer, et al., 2001).
Pregnancy has often been viewed as a “window of opportunity” as drug using women
may be more motivated to reduce or eliminate use for the sake of the unborn baby (Daley,
Argeriou & McCarty, 1998). Some women are able to do this on their own, while others may
need assistance (Ebrahim & Gfroerer, 2003). Pregnancy is therefore an ideal time for screening
and intervention, creating opportunities to positively impact public health. Unfortunately,
prenatal drug screening often does not occur because of such barriers as lack of provider time
and discomfort (Chasnoff, Neuman, Thornton, & Callaghan, 2001; Yarnall, Pollack, Ostbye,
1

Krause, Michener, 2003). Even if screening does occur, current screening methods fall short in
adequately detecting prenatal drug use. Screening measures rely extensively on self-report,
despite the documented issue of underreporting, and may lack utility in prenatal populations
(Skinner, 1982; Midank et al., 1998; Chasnoff et al., 2005). Prenatal care providers often do not
universally screen patients and face other barriers to identifying at-risk women (Chasnoff et al.,
2001; Anthony et al., 2010). Biological methods, while not limited by self-report bias, are less
useful because of their cost and level of invasiveness. The consequence of these limitations is
that prenatal drug use is often not identified at what would be a key time for intervention. New
strategies are needed to more accurately identify drug use during pregnancy.
Overall, the present study sought to compare different screening methods to a biological
measure of prenatal drug use. Specifically, the purpose of this study was to develop and validate
an indirect measure of drug use; one that would identify pregnant women who were continuing
to use drugs, regardless of their willingness to disclose such use. The research built upon the
recent work of Drs. Ondersma and Svikis who created the Wayne Indirect Drug Use Screener
(WIDUS; Ondersma, Svikis, Grekin, Lam, & Connors, 2009), developed to identify post-partum
women at risk for drug use during pregnancy.
Review of the Literature
In the following sections, I will introduce the issues of prenatal drug use and
underreporting. In doing so, I will present research on prevalence rates of drug use in the general
population and during pregnancy, factors commonly associated with drug use during pregnancy
and maternal, fetal, and infant consequences of prenatal drug use. Then, I will describe both
direct and indirect methods for detecting drug use during pregnancy, such as standardized
screening measures and biological measures, and also highlight the limitations of these
approaches. Next, I will elaborate on a recent study that utilizes an indirect method for
2

identifying prenatal drug use (i.e., the WIDUS) in order to provide a foundation for the current
study. Finally, I will conclude with a discussion of the current study’s aims and hypotheses.
Drug Use Prevalence
General population. Substance use is common in the general U.S. population. In a
recent Substance Abuse and Mental Health Services Administration (SAMHSA) National
Survey on Drug Use and Health (NSDUH), a representative sample of individuals ages 12 and
older (N = 68,000) was interviewed about recent (past 30 days) and lifetime use of alcohol and
other drugs. More than half of the sample (52%) reported consuming alcohol (beer, wine, liquor)
in the 30 days prior to completing the interview. Almost a quarter (23%) reported binge drinking,
defined as having five or more drinks on the same occasion on at least one day in the past 30
days. Heavy drinking or having five or more drinks on the same occasion on at least five days in
the past month was reported by about 7% of respondents. Current (past 30 days) use of a
tobacco product was also common, with over a quarter of respondents reporting use.
In this SAMHSA survey, “illicit drug use” focused on marijuana, cocaine, heroin,
hallucinogens, and inhalants as well as nonmedical use of prescription-type pain relievers,
tranquilizers, stimulants, and sedatives. Approximately 8% of the sample and 6% of female
participants reported recent use of at least one illicit drug. The most common drug used was
marijuana and was reported by three-quarters of current drug users and was commonly the only
drug used (57% of marijuana-users used only marijuana; SAMSHA, 2009). Marijuana was also
the most frequently used drug among women (4.4% of women reported using marijuana). After
marijuana, non-medically-used drugs were most commonly used (2.5% of the total samplep),
followed by crack/cocaine (0.7%) and hallucinogens (0.4%; SAMSHA, 2009).
While not all individuals who use substances go on to develop or currently have a
substance use disorder (SUD), a significant proportion of them do. Results from the same
3

NSDUH 2008 survey, indicated that almost 9% of respondents met Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) criteria for alcohol
and/or illicit drug abuse or dependence. Of these individuals, almost a third met criteria for illicit
drug abuse or dependence, either in combination with alcohol abuse or dependence or alone. The
rate of SUD for men was twice as high as the rate for women (12% versus 6%; SAMSHA,
2009).
Underreporting drug use. Prevalence rates of illicit drug use rely extensively on
individual’s self-report, as often only one method of data collection is used (i.e., paper-andpencil questionnaire, interview). Individuals’ disclosure of substance use is influenced by their
perceptions of social desirability. If they perceive that disclosure will be viewed negatively and
may result in negative consequences, they may underreport or minimize their drug use. Drug use
is often considered a sensitive behavior and especially given its illicit nature, individuals may be
uncomfortable admitting use (Fendrich, 2005). Individuals may also be more hesitant to admit
use of certain types of drugs, for instance, “harder” drugs (e.g., cocaine, amphetamine, and
heroin) that carry a much (remove) stronger stigma than marijuana (Weir, Stark, Flemming, He,
& Tesselaar, 1998). Consequently, self-reported drug use may not be a valid representation of an
individual’s actual use.
Biased self-reported drug use is problematic. When individuals distort their drug use it
leads to inaccurate prevalence rates, which may in turn negatively impact screening and
intervention efforts, as well as jeopardize the legitimacy of study conclusions (Macleod,
Hickman, & Smith, 2005). The validity of self-reported drug use has been examined by
comparing self-report to one or more biological measures of drug use (e.g., urinalysis, hair
analysis, meconium testing). Magura and Kang (1996) conducted a meta-analysis of 24 studies
involving self-report and biological measures of drug use in various high risk populations (e.g.,
4

individuals involved in the legal system, psychiatric inpatients, post-partum women referred to
drug treatment). Results indicated significant underreporting of self-reported drug use. While
underreporting may be expected in high-risk populations given the potential for negative
consequences of reporting drug use (e.g., legal charges), research has also provided support for
underreporting in general populations (Fendrich, Johnson, Wislar, Hubbell, & Spiehler, 2004;
Ledgerwood, Goldbeger, Risk, Lewis, & Price, 2008). In a random sampling of households in
Chicago (N = 627), biological testing revealed higher rates of heroin and cocaine use than selfreport estimated. Of those testing positive by biological measures (i.e., a positive hair, urine, or
saliva screen), only a quarter of individuals self-disclosed past year cocaine use and only onefifth disclosed past year heroin use. Interestingly, most individuals (78%) testing positive for
marijuana reported use in the past year, possibly reflecting the idea that marijuana is a lessstigmatized drug. Additionally, Fendrich and colleagues (2004) found that participants were
more willing to disclose lifetime drug use than recent use (i.e., past month, past year), suggesting
that lifetime drug use prevalence rates may be a more valid measure of drug use. Together, this
research underscores the need to acknowledge the impact of underreporting on rates of selfreported drug use.
Pregnant women. Although many women reduce or stop substance use during
pregnancy (SAMHSA, 2009; Ebrahim & Gfroerer, 2003), a significant proportion continue to
use substances during the prenatal period (Bailey, Hill, Hawkins, Catalano, & Abbott, 2008).
According to recent epidemiological data (2008 NSDUH), of pregnant women interviewed, ages
15 to 44 years, 11% reported current (past month) alcohol use, 4.5% reported binge drinking
(five or more drinks on one occasion) at least one day in the past month, and 0.8% reported
heavy drinking (having five or more drinks on one occasion on at least 5 days in the past month).
Cigarette smoking was more common than alcohol consumption among pregnant women: 16%
5

of respondents reported smoking at least one cigarette in the month prior to being interviewed.
Rates of drug use were lower with 5% of pregnant women reporting use of illicit drug in the past
month. Although the NSDUH did not break down prevalence of prenatal illicit drug use by type
of drug used, marijuana was the most commonly used drug by women of childbearing age
(SAMSHA, 2009). Research using an earlier version of the NSDUH survey also confirms this
finding (Ebrahim & Gfroerer, 2003). Overall, in considering NSDUH data, it is important to
recognize that these are conservative estimates of prevalence as the interviews focused only on
the past 30 days rather than the entire prenatal period.
Other studies focusing on specific samples (i.e., pregnant and postpartum women) and
utilizing a range of methodologies (i.e., self-report, biological testing, review of hospital records)
have found higher prevalence rates of prenatal substance use, specifically illicit drug use. Based
on a review of hospital records of all births occurring in a county hospital in San Francisco
during a 4-year period (July 1995-June 1999; N = 5940), 7% were determined to be drugexposed. Classification was based on maternal self-report of drug use, positive toxicology
screens during pregnancy, and/or positive toxicology screens in the newborn (Wolfe, Guydish,
Santos, Delucchi, & Gleghorn, 2007). Additional research utilizing toxicology screens at
delivery have documented even higher rates of prenatal illicit drug use (14%; Chasnoff,
Landress, & Barrett, 1990; Vega, Kolody, Hwang, & Noble, 1993).
Underreporting in pregnant women. Prevalence rates of illicit drug use during
pregnancy likely differ given the variability in methodologies used to detect use (e.g., interview,
questionnaire, biological testing of mother and/or infant), which is discussed in a later section,
and the types of populations studied (e.g., national, pregnant vs. postpartum, patients attending
prenatal care, treatment-seeking). In addition, the high-risk nature of prenatal drug use may also
lead women to underreport their use, making it difficult to obtain accurate prevalence rates
6

(Huang & Reid, 2006). Women who use drugs during pregnancy face social and legal
consequences, including social stigma, child protective services involvement, and loss of
custody, which leads them to underreport or minimize their drug use (Ondersma et al., 2000,
2001). Their fears of negative consequences are not unjustified. In South Carolina, child
protection laws include “viable fetuses” and thus pregnant women can be criminally prosecuted
with such charges as child abuse/endangerment and/or illegal drug delivery to a minor. In 1989,
the Medical University of South Carolina adopted policies which, in cooperation with a local
prosecutor, selectively screened urine samples from medically indigent obstetric patients for
cocaine metabolites. Those who screened positive were taken to the police, who then arrested the
pregnant women on charges of possession of an illegal drug and either delivery of drugs to a
minor and/or child abuse (Harris & Paltrow, 2003).
Not surprising given these consequences, there is often discrepancy between self-report
and biological measures of prenatal drug use. In a large, multi-site study of in utero cocaine
and/or opiate exposure, rates of maternal self-report of prenatal drug use differed from rates of
positive meconium analysis (Lester et al., 2001). Over 8,500 women were recruited shortly after
delivery from four sites, varying in race, ethnicity, social class, and geographic region. Based on
a maternal interview of past and current substance use, 661 (7.5% of the sample) women selfreported prenatal cocaine and/or opiate use. However, testing of infant meconium and
subsequent confirmation of positive screens identified an additional 254 drug-using mothers
(2.9% of the sample) who denied prenatal drug use. Therefore, based on a combination of
maternal self-report and meconium assays, 10.7% of all women used cocaine and/or opiates
during their pregnancy. Earlier studies utilizing large samples of pregnant women have also
noted discrepancies between self-report and toxicology screens (Frank, Zuckerman, Amaro,

7

Aboagye, Bauchner, Cabral, et al., 1988, Ostrea, Brady, Gause, Raymundo, & Stevens, 1992,
NIDA, 1996).
Drug Use and Pregnancy
Patterns of abstinence during pregnancy. As stated earlier, most women reduce their
use of illicit drugs during pregnancy, either by abstaining completely or decreasing the frequency
and/or quantity of their use (Ebrahim & Gfroerer, 2003). In addition, pregnant women may
engage in other harm reduction approaches, such as switching to a less potent type of drug (e.g.,
from hashish to marijuana; el Marroun, Tiemieier, Jaddoe, Hofman, Mackenbach, Steegers, et
al., et al., 2008). Data from the 1996-1998 National Household Survey on Drug Abuse (NHSDA;
now known as the NSDUH), suggests that cessation does not occur immediately after women
realize they are pregnant, but rather, during the third trimester most drug-using women report
abstinence. The proportion of drug-using women reporting abstinence increased by trimester:
28% were abstinent in their first trimester, 76% in their second trimester, and 93% in their third
trimester. The remaining 7% of drug-using pregnant women continued illicit drug use during
their third trimester. These statistics exemplify that although a small, but meaningful
nonetheless, percentage of women continued drug use throughout pregnancy; almost a quarter of
all drug-using women did not ultimately abstain until late in their pregnancy.
Frequency of drug use during pregnancy. When women continue using drugs into
their pregnancy they tend to be frequent users. In a study of prenatal care patients attending
urban healthcare centers in Minnesota (N = 1492), women who reported drug use at their first
prenatal visit typically reported weekly or daily use of illicit drugs, as opposed to rare or monthly
use (Harrison & Sidebottom; 2009). Researchers in the Netherlands (el Marroun et al., 2008)
found similar results in their population-based study of pregnant women (N = 7531). Women
who self-reported prenatal cannabis use (the drug of interest in this study) were most often
8

frequent users (80% used daily or weekly). Women who did not report prenatal use were likely
monthly users. Additionally, pregnant women with a history of cannabis dependence were
almost three times more likely to use prenatally (OR = 2.77, p < .001) than women with no
history. Together, these findings of frequent use highlight the dependent nature of drug use
during pregnancy and the difficulty of abstaining.
Patterns of substance use. Not only does the frequency of substance use change during
pregnancy, patterns in the type of substance used from pre-pregnancy to pregnancy may also
differ. This has been shown specifically among low-income populations. Harrison and
Sidebottom (2009) interviewed women attending their first prenatal care appointment (N =
1,492) about their pre-pregnancy and prenatal (use that occurred after a woman found out she
was pregnant) use of substances. The majority of participants were non-Caucasian (43.7%
African American), young (mean age = 22.6 years), and low-income (90% received services
through Medicaid or a state-funded program). Pre-pregnancy (12 months prior to pregnancy)
substance use rates indicated that alcohol use was almost twice as common as drug use (41.1%
vs. 24%). Interestingly, prenatal use showed the opposite pattern: almost twice as many women
reported recent illicit drug use as recent alcohol use (10.7% vs. 5.6%). More specifically, drug
use alone, as opposed to alcohol use alone or concurrent alcohol and drug use, was the most
common substance use pattern reported during pregnancy. Further, the rate of women continuing
substance use after they discovered they were pregnant was higher for drugs than alcohol (44%
vs. 13%). In a smaller sample of prenatal patients (N = 130) with comparable demographics, the
same pattern was true: women tended to report prenatal marijuana use more often than alcohol
use (17% vs. 7%; Jesse, Graham, & Swanson, 2006). Overall, these findings underscore the need
to address illicit drug use during pregnancy. Moreover, as with all self-reported rates, it is
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important to consider the possibility that these percentages may be even higher because of
underreporting.
Factors associated with prenatal drug use. In an attempt to improve screening and
identification of drug-using pregnant in prenatal care clinics, a growing body of research has
examined factors associated with prenatal drug use. Unfortunately, the majority of these studies
relied on women’s self-reported drug use to identify risk factors. As previously mentioned, this
reliance on self-report is problematic given the frequency of underreporting by pregnant women.
Nonetheless, the research is still informative as a first step towards better identification of
prenatal drug use.
Researchers have utilized both nationally representative and convenience (e.g.,
university-based obstetrics clinic, county hospitals) samples of pregnant women to identify
correlates of drug use. A variety of factors have been examined, including demographic, social,
psychological, experiential and pregnancy-related factors (Havens, Simmons, Shannong, &
Hansen, 2009; Ebrahim & Gfroerer, 2003; Marcenko & Spence, 1995; Kelly, Zatzick, & Anders,
2001; Horrigan, Schroeder, & Schaffer, 2000; Jesse et al., 2006).
While studies have used different methodologies, common correlates of prenatal drug use
have been identified. Demographically, pregnant drug-using women are more likely than nonusers to be unmarried (Havens et al., 2009; el Marroun et al., 2008; Wolfe et al., 2007; Huang &
Reid, 2006; Ebrahim & Gfroerer, 2003), older (Harrison & Sidebottom, 2009), unemployed or
never worked (Havens et al., 2009; Huang & Reid, 2006), receiving public assistance (Huang, &
Reid, 2006; NIDA, 1996) and have less education (Ebrahim & Gfroerer, 2003). Prenatal drugusers are also more likely to be experiencing current psychopathology, including depression,
anxiety and suicidality (Havens et al., 2009; Jesse et al., 2006; Chasnoff, Neuman, Thornton, &
Callaghan, 2001; Horrigan et al., 2000). They also often live with another adult who uses illicit
10

substances, have a family member with a drug or alcohol problem (Chasnoff et al., 2001;
Marcenko & Spence, 1995), and have experienced some form of abuse and/or childhood trauma
in their lifetime (Horrigan et al., 2000; el Marroun et al., 2008; Marcenko & Spence, 1995).
Delinquent behavior (i.e., having ever been arrested or having a criminal record) was also found
to be a significant predictor of prenatal drug use (el Marroun et al., 2008). Additionally,
women’s past and current substance use may be a useful indicator of current drug use. Prepregnancy and current cigarette smoking and alcohol use (Harrison & Sidebottom, 2009; Svikis,
Henningfield, Gazaway, Huggins, Sosnow, Hranicka et al., 1997; Chasnoff et al., 2001; el
Marroun et al., 2008), as well as pre-pregnancy drug use (Harrison & Sidebottom, 2009), have
been found to be significantly associated with prenatal drug use.
Research has also demonstrated associations between prenatal drug use and factors
associated with low socio-economic status, including lack of transportation (Harrison &
Sidebottom, 2009), housing instability (Chasnoff et al., 2001), and food insecurity (Harrison &
Sidebottom, 2009). Some studies also suggest an association between prenatal drug use and
sexually transmitted diseases (Horrigan et al., 2000; Berenson, Wilkinson, & Lopez, 1995).
Additionally certain pregnancy-related factors, such as number of previous live births
(Bendersky, Alessandri, Gilbert, & Lewis, 1996; Marcenko & Spence1995), history of preterm
birth (Jesse et al., 2006; ), unintended pregnancy (el Marroun et al., 2008; Hunay & Reid, 2006),
and seeking prenatal care later in pregnancy (Marcenko & Spence, 1995) have been associated
with prenatal drug use. However, the correlates of age and previous live births/number of
children are confounded by the length of time a woman has used drugs and therefore, may act as
a proxy for substance use disorder chronicity (Johnson, McCarter, & Ferencz, 1987). Lastly,
women who used drugs during pregnancy compared to those who did not more often reported
that the father of their baby also used drugs (el Marroun et al., 2008).
11

In utero effects of illicit drug use. When a pregnant woman consumes drugs, the
substance crosses the placenta thereby exposing the fetus. Consequently, in addition to the
general health risks associated with drug use for the mother, prenatal drug use poses risk to the
developing fetus. Prenatal exposure is associated with a variety of perinatal complications
including higher rates of spontaneous abortion, stillbirth, placental insufficiency, eclampsia,
gestational diabetes, fetal growth retardation, low birth weight and premature labor (Finnegan,
1994; Kennare, Heard, & Chan, 2005; Burns, Mattick, & Cooke, 2006). Not surprising given
these consequences, drug-exposed infants tend to require more significant medical attention than
non-exposed infants and are a greater socio-economic cost to society (Finnegan, 2000; Huestis &
Choo, 2002). Prenatal drug exposure not only affects the fetus and infant, but can also impact the
later cognitive and behavioral development of the child. While the specific long-term
consequences vary by type of drug, prenatal exposure has been associated with lower IQ scores,
increased behavioral problems, poor attention, impulsivity, impaired executive functioning and
poor state control (Huestis & Choo, 2002; Behnke & Eyler, 1993).
Research has shown that the link between prenatal drug use and negative outcomes is
more complicated than direct causation. The effect of prenatal drug use on fetal and infant
outcomes varies as a function of the type of drug use (i.e., type of drug, quantity, frequency, and
duration) and individual characteristics (i.e., how an individual responds physiologically and
psychologically to drugs). Environmental factors associated with prenatal drug use (e.g., low
SES, poor prenatal care, poor nutrition) also contribute to negative outcomes, making it difficult
to disentangle the unique effects of prenatal drug exposure (Anthony, Austin, & Cormier, 2010;
El-Mohandes, Herman, Nabil El-Khorazaty, Katta, White, & Grylack, 2003). In addition, polysubstance use further complicates researchers’ ability to identify specific adverse consequences
of specific drugs (Kandall, Doberczak, Jantunen, & Stein, 1999). Despite the many confounding
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factors, there is still a great need for early detection and intervention of prenatal substance use in
order to improve negative fetal/infant/child outcomes. Early work by Chasnoff and colleagues
(1989) highlights this window of opportunity: drug-using women who become abstinent by their
third trimester have been found to significantly reduce the risk of medical complications.
Unique circumstances of pregnancy. Pregnancy is a unique time for identification and
intervention of problematic substance use. Most women stop using substances while they are
pregnant, but often return to drug use during the postpartum period (SAMSHA, 2009; Ebrahim
& Groerer, 2003). For those women who continue using into and throughout their pregnancy,
their use of illicit drugs may be considered problematic and may even reflect addictive behavior
(el Marroun et al., 2008). It is well known that most individuals with a substance use disorder do
not seek treatment (SAMSHA, 2005). Thus, during pregnancy, when women are accessing
health services more regularly than if they were not pregnant, is an ideal time to detect
problematic drug use and to intervene. Motivation to seek help may be greater during this time
because of women’s concerns about the health of their fetus (Grella, 1999), their own health
(Gehshan, 1995) and fear of negative consequences (e.g., the legal implications of testing
positive at delivery; Howell & Chasnoff, 1999). In a retrospective study utilizing county hospital
and drug treatment service records, Wolfe and colleagues’ (2007) results support the notion of
increased motivation during pregnancy. They found that significantly more women engaged in
some form of drug treatment (i.e., outpatient, residential, methadone maintenance, or
detoxification) during or after delivery than they did one year prior to becoming pregnant.
Further, during pregnancy, substance-using women have the opportunity to reduce the harm to
their fetus by quitting or cutting down whereas after delivery that window of opportunity expires.
Although pregnancy is an ideal time for intervention, many drug-using women are not identified
by their prenatal care providers, resulting in missed opportunity. Consequently, the ability to
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refer and engage drug-using women in treatment rests on how well screening methods identify
prenatal drug use.
Detecting Drug Use during Pregnancy
A variety of methodologies, including biological testing and self-report questionnaires,
have been developed to screen for problematic substance use. The purpose of screening is not to
diagnose substance abuse or dependence, but rather to identify individuals who may be at-risk
for these problems in order to facilitate referral for additional assessment and intervention. Given
this purpose, priority is often given to sensitivity, the true positive rate of a screening tool, over
specificity, the true negative rate. No matter the type of method used, accurate identification is
extremely important as brief intervention and treatment efforts can only occur following proper
identification of problematic drug use. Health care providers, particularly primary care providers,
are in a unique position to screen for substance use problems because of their regular access to
patients over time and because such questions are relevant to their health. In addition, because a
woman’s obstetrician or gynecologist may function as her primary care physician (Klock, 2004),
screening for prenatal drug use in OB/GYN clinics is ideal. During pregnancy, universal
substance use screening at the first prenatal care visit (ACOG, 2006; Welch & Sokol, 1994), as
well as throughout pregnancy (Svikis & Reid-Quinones, 2003) is recommended. When screening
occurs, providers rely on a variety of methods.
Biological screening methods. Drug screening or “drug testing” has become somewhat
synonymous with biological methods, where a biological specimen (i.e., urine, hair, blood,
saliva) is analyzed for the presence of different kinds of drugs and their metabolites. To identify
prenatal drug use, both maternal and infant specimens can be analyzed. For instance, testing of
infant meconium (i.e., the first stool of the newborn infant) post-delivery has been used to
determine whether a woman used substances during her pregnancy (Bessa, Mitsuhiro, Chalem,
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Barros, Guinsburg, & Laranjeira, 2010). Screening for illicit drugs often consists of an initial test
using an immunoassay to determine whether or not a drug or its metabolite is present and then
confirmatory testing that is qualitatively different from the initial test (e.g., chromatography/mass
spectrometry) is conducted. The Substance Abuse and Mental Health Services Administration
(SAMSA) established drug-specific cut-off points to standardize the results of drug testing.
Methods vary with respect to their window of drug detection, the amount of time after ingestion
during which the substance can be detected, whether results are qualitative (positive or negative
for a particular drug) or quantitative (the level of the substance used) and their level of
invasiveness. Consequently, each method has strengths and limitations (Wolff, Farrell, Marsden,
Montiero, Ali, Welch, et al., 1999). Unfortunately, biological screening is often used when a
provider suspects a pregnant woman is using drugs, but denies such use (Svikis & Huggins,
1996).
Urine testing. Urinanalysis is a well-accepted method for detecting drug use because
urine samples are easy to collect in sufficient quantities necessary for testing. In addition, drugs
and their metabolites are usually present in urine in high concentration. Relative to other
methods, urinanlysis has a short window of detection (i.e., 1-3 days) for most drugs, with the
exception of marijuana, and therefore only identifies recent drug users. Use of marijuana can be
detected in urine for weeks after last use. Another drawback to urine screening is that the sample
can be easily adulterated to produce a false negative; however, temperature and pH tests can be
used to determine the authenticity of samples (Wolff et al., 1999).
Hair testing. Hair analysis is another biological method to detect drug use and provides a
“retrospective calendar” of use (Kintz, Villain, & Cirimele, 2006). Hair grows approximately one
cm/month and so different sections of hair can be analyzed to create a timeline of use during
pregnancy. Thus, hair analysis is considered advantageous over urinalysis because of its longer
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window of detection. Research has also shown this method to have excellent sensitivity in
detecting perinatal drug use (Ostrea, Knapp, Tannenbaurm, Ostrea, Romero, Salari, et al., 2001).
However, this method is not without limitations. Although collecting a hair sample may be less
invasive than collecting urine or blood, some women may be opposed to providing a hair sample
because of cosmetic concerns or taboos (Eyler, Behnke, Wobie, Garvin, & Tebett, 2005). In
addition, the results of hair analysis can be affected by individual and racial differences (i.e., hair
color and texture), with coarser, darker hair incorporating more of a drug than thinner, lighter
hair (Ebrahim & Gfroerer, 2003). Chemical processing (i.e., coloring, bleaching, straightening),
and external exposure to drugs (e.g., hair tests positive for marijuana because of passive
exposure to smoke rather than active ingestion) also impact test results.
Blood testing. Although drug testing blood samples is useful quantitatively, it is also a
very invasive procedure which requires trained personnel and special handling procedures.
Further, it may not be as useful as urine testing because most illicit substances leave the blood
within a few hours of use and concentrations fall below threshold levels of detection (Wolff et
al., 1999). These drawbacks limit the utility of blood testing as a screening tool in pregnant
women.
Saliva testing. Collection of saliva is easy and less invasive than collecting other
biological samples. The window of detection for oral fluid ranges from five to 48 hours and is
typically shorter than that of urine (Verstraete, 2004). In a study of pregnant opiate-dependent
women, saliva testing was a highly sensitive method for detecting opiate and cocaine use (Dams,
Choo, Lambert, Jones, & Huestis, 2007). However, the authors acknowledge that rates of
detection will vary by cut-off concentrations, type of collection device, and detection method
used. Thus, while it is a promising alternative to more invasive methods, additional research is
needed to standardize the collection and testing of oral fluid.
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Infant specimen testing. Testing newborn’s hair, urine and meconium are additional
methods to detect prenatal drug use. Drugs and their metabolites are believed to accumulate in
meconium at about 18 weeks gestation, when it is first produced, allowing drug use in the second
and third trimesters to be detected (Ostrea, et al., 1992). This method provides a longer window
of detection over oral fluid and urine testing. In addition, drug and metabolite concentrations
may be higher in meconium than urine (Ostrea, Brady, Parks, Asensio, & Naluz, 1989). Hair
taken from an infant may offer a more pure calendar of a mother’s drug use than her own hair as
it has not been subject to the same contaminants (e.g., chemical processing, external exposure to
drugs). However, a newborn may not have enough hair to adequately test for exposure to drugs
(Eyler et al., 2005). Urine testing may be a useful alternative; however, this method is still
limited to only recent drug use by the mother.
Summary of biological methods. A variety of biological specimens have been used to
detect prenatal drug use, including urine, hair, blood, oral fluid, and meconium. As elaborated
above, each method has strengths and limitations. For detecting prenatal drug use, no biological
method has been identified as the “gold standard.” Drug testing does help identify women who
deny use; however it may not be a cost-effective approach (Eyler et al., 2005). Further,
identifying prenatal drug use at delivery (i.e., by testing infant specimens) prevents the
possibility of early intervention and reducing harm to the fetus/infant.
Direct screening methods. While many screening tools have been developed to assess
at-risk drinking, a lesser number of measures exist to detect illicit drug use and problems.
Furthermore, many of the existing screeners for problematic drug were adapted from or patterned
after alcohol screening tools (e.g., the word, “drinking,” was replaced with “drug use” in the
Drug CAGE). To an even lesser extent have measures been developed for or validated on
pregnant women. Most screeners are direct or face-valid (i.e., they ask specifically about
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substance use and its consequences), rely on individuals’ self-report and are administered as
paper-and-pencil questionnaires or brief interviews. Examples of specific direct to screen for
prenatal drug use are described below.
Drug CAGE. The Drug CAGE is a 4-item, yes/no questionnaire designed to detect
problematic drug use by asking: 1) Have you ever felt you should cut down on your drug use?; 2)
Have people annoyed you by criticizing your drug use?; 3) Have you ever felt bad or guilty
about your drug use?; and 4) Have you ever used drugs first thing in the morning to steady your
nerve? The CAGE was originally developed to screen for problem drinking (Ewing, 1984) and
has become a widely-used alcohol screening tool for a variety of populations (Bradley, BoydWickizer, Powell, & Burma, 1998; Bradley, Kiylahan, Daniel, Bush, McDonell, Fihn et al.,
2001; Satre, Knight, Dickson-Fuhrmann, & Jarvick, 2004; Williams, Horton, Samet, & Saitz,
2007), including pregnant women (Russell, Martier, Sokol, Mudar, Bottoms, Jacobson et al.,
1994; Russell, Martier, Sokol, Mudar, Jacobson, and Jacobson, 1996). Additionally, the CAGE
was adapted to assess general substance use (i.e., use of alcohol and/or drugs; Brown & Rounds,
1995) and also drug use (Midanik, Zahnd, & Klein, 1998; Kelly et al., 2001). A positive response
to at least one of questions signifies at-risk substance use (Bradley, Kivlahan, Bush, McDonell,
& Fihn, 2001).
Midanik and colleagues (1998) modified the CAGE for use as a prenatal drug screener in
a racially diverse sample of pregnant women (N = 1147) recruited from non-medical settings
(e.g., community organizations and social service agencies). They argued that the open
timeframe (i.e., have you ever) limits the CAGE’s utility in pregnant women and so they
restricted questions to the 12 months prior to pregnancy recognition. This adapted version of the
Drug CAGE was validated against self-reported drug use, which was broken down into lighter
drugs (i.e., uppers, diet pills, stimulants, tranquilizers, sleeping pills, valium, morphine, other
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pain killers, sedatives), heavier drugs (i.e., cocaine/crack, methamphetamine, ice, heroin,
methadone, speedballs) and marijuana/hashish, during the same time period. Sensitivity or the
proportion of self-reported drug users who screened positive on the CAGE and specificity, the
proportion of self-reported non-users who screened negative on the CAGE, of this adapted
measure were evaluated. Results indicated very low sensitivity for lighter drugs and marijuana
and higher sensitivity for harder drugs. Specificity was high no matter the type of drug used.
Thus, for lighter drugs and marijuana, the Drug CAGE does not appear to be an effective
screening tool for pregnant women. However, an argument can be made to support the measure’s
utility in identifying women at risk for heavier drug use. According to ROC analysis, a cut-off of
1 was found to be the optimal score to optimize both sensitivity and specificity. However, when
sensitivity is valued over specificity, a cut-point of 3 was recommended to identify harder
prenatal drug use.
While this research is informative, Midanik and colleagues’ (1998) results must be
viewed in consideration of a major limitation: the study relied completely on pregnant women’s
self-reported drug use to validate the modified CAGE. As previously described, underreporting
is common among pregnant women. Thus, it is imperative for future research examining the
utility of the drug CAGE as a screening tool for prenatal drug use to employ drug use criterions
that are less vulnerable to self-report bias (i.e., biological measures).
DAST. The Drug Abuse Screening Test (Skinner, 1982) is another commonly-used
screening tool for problematic drug use. The self-administered questionnaire was developed by
adapting items from the Michigan Alcoholism Screening Test (MAST; Selzer, 1971) and exists
in three versions (10-, 20- and 28-items). The yes/no items measure consequences of drug use
and other factors associated with drug use disorders. The measure in varying forms has been
widely used in a number of populations, including individuals with known drug problems
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(Gavin, Ross, & Skinner, 1989; Bohn, Babor, & Kranzler, 1991; Kush & Sowers, 1996),
psychiatric patients (Staley & El-Guebaly, 1990), union members (El-Bassel, Schilling, Schinke,
Orlandi, Wei-Huei, & Back, 1997) and female offenders (Salstone, Halliwell, & Hayslip, 1994).
In a review of the DAST’s psychometric properties (Yudko, Lozhkina, & Fouts, 2007),
the measure showed good internal consistency (α ranged from .74- .94) and test-retest reliability
(r ranged from .71- .85). Evidence was also found to support the criterion and construct validity
of the DAST. Additionally, the measure’s discriminative validity (i.e., its ability to separate
individuals with and without drug use disorders) was examined by comparing scores on the
DAST against a criterion measure, either a psychiatric diagnosis of substance abuse or
dependence or symptoms of the disorders. Overall, sensitivity and specificity was extremely
variable and differed based on the population of interest, version, type of criterion (presence of a
diagnosis or symptoms) and cutoff score used (Yudko et al., 2007). Interestingly, the DAST has
only been compared to measures based on self-report (e.g., other screening instruments or a
structured clinical interview).
The DAST is a face-valid measure: if an individual does not want to be identified with
drug problems, then he or she can easily provide responses that are not indicative of a problem. It
is not surprising then that the DAST has been found to be negatively correlated with both social
desirability (r = -.38, p < .001) and denial (r = -.28, p < .001; Skinner, 1982). In an employment
setting, where negative consequences are possible, a stronger relationship was seen between
DAST scores and social desirability (r = -.47; El-Bassel et al., 1997). Together, these results
question the utility of the DAST with individuals who may be motivated to minimize or conceal
drug use (e.g., in the workplace, criminal justice settings). Additional research with the DAST is
needed in order to determine its usefulness in populations vulnerable to underreporting.
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Drawbacks of the Drug CAGE and DAST. While the CAGE and the DAST have been
commonly used, their application to pregnant women is still questionable. First, these measures
have only been validated against self-reported criterions. In the study by Midanik and colleagues
(1998) the criterion was self-disclosed drug use in the 12 months prior to pregnancy recognition.
In the case of the DAST, a diagnosis of drug abuse or dependence, which is primarily based on
self-report, was frequently used as the criterion for drug problems (Cocco & Carey, 1998;
Maisto, Carey, Carey, Gordon, & Gleason, 2000). In these studies, self-report was validated
against self-report. This is problematic given that self-report relies on individuals’ accuracy in
reporting their own behavior and thus may be biased. Furthermore, the screening tools described
above may also be inappropriate for pregnant women given that their purpose is to identify
problematic drug use (i.e., drug use and associated problems that reach a diagnosable level).
During pregnancy, any use of illicit drugs can be considered problematic given the possible
negative effects on the fetus. Consequently, a woman’s drug use does not need to meet a
diagnosable level in order for her to be at-risk and so she may be missed on a screening tool
designed to detect problematic use (Anthony et al., 2007).
The 4P’s Plus. The 4P’s Plus is a short, five-question screening tool administered by
prenatal care providers to identify pregnant women in need of additional assessment and/or
monitoring of their alcohol, tobacco, and/or illicit drug use (Chasnoff, McGourty, Bailey,
Hutchins, Lightfoot, Pawson, et al., 2005). Questions ask women about their parents’ and
partner’s problems with alcohol and/or drugs, use of alcohol in the past and use of alcohol and
cigarettes in the month prior to becoming pregnant. A woman is considered to have a “positive”
screen if she admits use of alcohol or tobacco in the month before she knew she was pregnant.
The 4P’s Plus is considered an effective and easy to administer tool to identify women at highest
risk of prenatal substance use (Chasnoff et al., 2005).
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Direct methods and self-report. The direct screening methods discussed above are facevalid techniques that rely on self-report. Self-report is problematic because it is vulnerable to
forgetting. Individuals may inaccurately recall the frequency, duration, and quantity of their drug
use (Lester et al., 2001). Additionally, individuals can also easily deny or minimize their drug
use if they do not want to be identified. Research has shown that individuals tend to underreport
or minimize their substance use (Magura & Kang, 1996). As previously mentioned, this is not
only true in the general population, but also among pregnant women (Frank et al., 1988, Ostrea
et al., 1992, NIDA, 1996), whose disclosure of use carries significant legal and social
implications (Derauf, Katz, & Easa, 2003; Markovic, Ness, Cefilli, Grisso, Stahmer, & Shaw,
2000; Harrison, Haaga, & Richards, 1993).
Translational issues with direct screening methods. While direct screening methods
may be useful to a certain degree, there are other issues that impact the utility of direct prenatal
drug screening. In addition to self-report bias, providers themselves can be a source of bias.
Although ACOG recommends universal screening of all pregnant women, regardless of their
social status, educational level, race, or ethnicity (ACOG, 2006), this does not necessarily always
occur. Providers may selectively screen women based on their own biases (i.e., they may only
ask the women who they think are using drugs during pregnancy). For instance, they may decide
to screen on the basis of pregnancy complications, poor pregnancy outcomes or correlates of
drug use, instead of screening universally (Weir et al., 1998).
Chasnoff, Landress, and Barrett (1990) examined the rate of illicit drug use among all
women seeking prenatal care at five public health clinics (n = 380) and 12 private obstetrical
offices (n = 335) in Pinellas County, Florida, where reporting of known prenatal drug use is
mandated by law. Prevalence rates of drug use were compared to providers’ post-delivery reports
to health authorities of women who used drugs prenatally. The study found that providers were
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10 times more likely to report African American women than Caucasian women to authorities
even though their rates of drug use were similar. In addition, women of lower socio-economic
status were more likely to be reported than women of higher SES. Sadly, similar racial and
economic biases were also found in a more recent study of provider decisions to test for illicit
prenatal drug use (Veda Kunins, Belline, Chazotte, & Du, 2007). Given these biases, it is not
surprising that pregnant African American women and women of lower SES are more likely to
underreport their drug use, especially under non-anonymous screening conditions (Chasnoff et
al., 1990; Alvik, Haldorsen, & Lindemann, 2005).
In addition to provider bias, additional barriers prevent identification of women at-risk
for prenatal drug use. Such obstacles include providers’ lack of knowledge and skill of how to
screen effectively and intervene with positive screens (Chasnoff et al., 2001; Miller, Ornstein,
Nietert, & Anton, 2004), time constraints (Yarnall et al., 2003) and lack of familiarity with
resources and referral sources (McLellan, Lewis, O’Brien, & Kleber, 2000; Trude & Soddard,
2003). In addition, providers may be deterred from asking women about their substance use
because of the possible legal implications of a positive response or because they feel
uncomfortable doing so and fear offending their patients (Anthony et al., 2010; Chasnoff et al.,
2001; Chavkin, 1990; Morse, Gehshan, & Hutchins, 1997). Regardless of the reason why health
care providers are not universally screening prenatal care patients for substance use, the
consequence is the same: women who use illicit drugs prenatally are, for the most part, “missed”
at a critical time for intervention.
Indirect methods. Given the limitations of current screening tools, efforts have been
made to utilize indirect techniques for identifying substance abuse. Such instruments attempt to
circumvent the issue of underreporting by avoiding obvious questions about substance use.
Subscales on the Minnesota Multiphasic Personality Inventory- 2 (MMPI-2) and the Substance
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Abuse Subtle Screening Inventory (SASSI-3; Miller & Lazowski, 1999) are examples of such
indirect measures.
MMPI-2 subscales. The MacAndrew Alcoholism Scale-Revised (MAC-R; MacAndrew,
1965) and the Addiction Potential Scale (APS; Weed, Butcher, McKenna, & Ben-Porath, 1992)
are two subtle scales designed to distinguish between individuals with substance use disorders
and controls. Both scales were developed by identifying items that differentiated individuals with
a known SUD (e.g., inpatients at a chemical-dependency program) from individuals with no
SUD (e.g., psychiatric inpatients, individuals from the MMPI-2 normative sample). MMPI items
included in these scales do not deal directly with substance use but rather reflect personality
dimensions and life situations frequently endorsed by individuals with a SUD. For example,
factor analysis of the APS revealed six factors: harmful habits, positive treatment attitudes,
forthcoming, hypomania, risk taking, and passivity (Weed, Butcher, & Ben-Porath, 1995).
Among treatment-seeking individuals, the APS was found to have poor sensitivity (.46-.64;
Rouse, Butcher, & Miller, 1999; Stein, Graham, Ben-Porath, & McNulty, 1999). More recent
research using a structured clinical interview as the gold standard found no clinical utility for the
APS (Clements & Heintz, 2002). Similar to psychometric studies with direct measures, the “gold
standard” was a self-report measure, so self-report was again validated against self-report. An
additional limitation of MMPI scales is that development was limited to items already part of the
MMPI-2; thus, many possible items of potential utility in predicting drug use among pregnant
women (e.g., pregnancy-related variables) could not be considered.
Substance Abuse Subtle Screening Inventory. The Substance Abuse Subtle Screening
Inventory (SASSI-3; Miller & Lazowski, 1999) is a 93-item proprietary measure comprised of
both indirect and direct items designed to screen for substance dependence. One scale is
comprised of 67 true/false items that are both indirect (e.g., “I am rarely at a loss for words”) and
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direct (e.g., “I have used alcohol or ‘pot’ too much or too often”). The authors recommend
administering this scale first, before the second scale, which is composed of 26 Likert-scaled
questions that ask directly about substance use and its negative consequences. The SASSI
includes four clinical subscales (Face Valid Alcohol, Face Valid Other Drugs, Obvious
Attributes, and Subtle Attributes), two defensiveness subscales (Defensiveness and Supplemental
Addiction Measure) and either two or three supplementary subscales (Random Answer Pattern,
Corrections, and Family Problems). Scores on the SASSI are interpreted according to decisions
rules and thus individuals are classified as “high probability of having a substance dependence
disorder” if their profile meets criteria for one of the conditions (e.g., above the 84th percentile
on any two clinical subscales). Empirical evidence supporting the SASSI is weak. One peerreviewed study comparing scores on the measure to urinalysis data, found that the measure failed
to identify 45% of pregnant women who tested positive for drugs (Horrigan & Piazza, 1999).
Further, a recent review of the SASSI’s psychometric properties (N = 36 articles) “found no
independent empirical evidence that the SASSI is more sensitive or accurate or less susceptible
to falsification in screening for SUDs than simpler direct scales [e.g., CAGE, Michigan
Alcoholism Screening Test, Alcohol Use Disorders Identification Test] available in the public
domain” (Feldstein & Miller, 2007, p. 47). The authors of the review also concluded that it is
unclear what the indirect scales are measuring: the indirect items purport to assess correlates of
SUDs, although the nature of these traits is not clearly specified and have been found to change
with treatment.
Summary of indirect methods. Overall, existing measures that rely on subtle or indirect
methods of identification (i.e., the subscales on the MMPI-2 and the SASSI, described above) do
not appear to be well-suited for use as a screening tool for pregnant women in prenatal care
settings. While an indirect methodology may limit socially desirable responding, clearly
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additional research is needed to develop a more time- and cost-efficient screening tool to better
detect prenatal drug use.
New direction with an indirect method. In a recently completed project, Drs. Ondersma
and Svikis examined indirect drug screening involving validation with objective measures of
drug use in a sample of post-partum women at an urban, obstetric hospital in Detroit, Michigan.
A checklist of indirect factors associated with drug use disorders, the Wayne Indirect Drug Use
Screener (WIDUS; Ondersma et al., 2009) was validated against hair and urine analysis. This
corroboration using biological testing was a key methodological advantage over previous efforts
to identify an indirect measure.
The WIDUS. The WIDUS is a true/false index of items known to tap correlates of drug
abuse and dependence. The creation of this measure reflected Newcomb and Feliz-Ortiz’s (1992)
epidemiological/cumulative stress and resiliency model which conceptualizes risk as multiplydetermined, emphasizing both protective and risk factors. In order to identify correlates of drug
use, an extensive literature review was conducted by Dr. Ondersma and his colleagues. The
domains sampled from correlational research included the following: (1) behavioral correlates,
such as tobacco or alcohol use, emergency room use, gambling, fighting, promiscuity, criminal
behavior, and less involvement in school, work, or religious activities; (2) medical correlates,
such as chronic illness, sexually transmitted diseases, and dental problems; (3) psychological
correlates, including depression, anxiety (particularly those associated with PTSD),
neurobehavioral disinhibition in childhood (such as oppositional or conduct disorders), risk
taking, sensation-seeking, and attitudes/expectancies consistent with drug use; (4) experiential
correlates, such as having experienced trauma, childhood abuse, automobile accidents, blackouts,
running away as a youth, time in foster care or group homes, interpersonal victimization,
violence exposure, and poor parental bonding; and (5) demographic correlates, including being
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younger, unemployed, unmarried, or a recipient of some form of public assistance. For a more
complete list of correlates and their references, please see Appendix A. Protective factors in all
of these areas, such as law abidance, religious involvement, self-acceptance, and positive
relationships with parents (Newcomb & Felix-Ortiz, 1992), were also included along with risk
factors in order to provide a more complete picture of overall risk.
Items reflecting each drug use correlate and protective factor were generated and
combined to form an initial item pool. A panel of experts, Dr. David Streiner, a statistician and
psychometrician, Dr. Ralph Tarter, creator of the Drug Use Screening Inventory (DUSI) and Dr.
Charles R. Schuster, a senior drug abuse researcher, reviewed the items. Following expert
review, a small sample of post-partum women (N = 10), who had recently delivered at Hutzel
Women’s Hospital in Detroit, Michigan, rated the initial item pool on the clarity, interpretation,
and acceptability of each item. After incorporating this feedback into a finalized version, the
127-item measure was administered via an audio-enhanced computer-assisted self-interview (ACASI) software program to a sample of 400 post-partum women recruited from their postdelivery hospital rooms. The software relied on a three-dimensional cartoon character, Peedy the
parrot, to provide instructions and guide the particpant through the questionnaire. Following
completion of the WIDUS, hair and urine samples were collected. Data analysis identified a
subsample of seven items that best predicted drug use (i.e., positive by urine and/or hair testing).
These items are presented in Table 1.
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Table 1
WIDUS Items
#
Item
1
I am currently married
2
In the past year, I have been bothered by pain in my teeth or mouth
3
I have smoked 100 cigarettes in my entire life
4
There have been times in my life, for at least two weeks straight, where I
felt like everything was an effort
5
Most of my friends smoke cigarettes
6
I get mad easily and feel a need to off some steam
7
I often have trouble sleeping
Dr. Ondersma’s study also involved an additional component that addresses what to do
when women screen positive on the WIDUS. Women who screen positive on an indirect
screener cannot be viewed as known drug users. Consequently, traditional methods of
intervention would not apply. Dr. Ondersma and his colleagues developed an indirect, brief
intervention software program designed to promote self-change or treatment-seeking among
women who screen positive. The intervention is a single, 20-minute session that addresses
substance use indirectly within topics of emotional health, healthy lifestyle and safety in and
around the home. Therefore, the intervention is still relevant to women who are falsely identified
as drug users by the WIDUS (i.e., false positives).
Overall, the development and validation of the WIDUS represents a significant effort to
improve the identification prenatal drug use. Most importantly, this screening tool was developed
and validated against non-self-report measures of drug use (i.e., urine and hair assays), unlike
other commonly-used screeners which were validated against self-report. This measure was also
developed within the context of anonymity and using ACASI technology, both of which have
been shown to reduce underreporting (Durant, Carey, & Schroder, 2002; Newman et al., 2002).
Finally, the WIDUS is an innocuous, indirect measure of drug use and thus likely to minimize
the amount of underreporting present with direct screening tools.
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Current Study
The purpose of the current study was to develop and validate an indirect measure of drug
use that can identify pregnant women who have a history of recent drug use, regardless of their
willingness to disclose such use. The study built upon the work of Drs. Ondersma and Svikis in
order to examine what indirect items best predicted drug use in this sample of pregnant women.
Specifically, four questions were asked to guide this research:
1)

Are women in this population underreporting the incidence of prenatal drug use? If
so, what is the extent of the discrepancy between self-report and UDS?

2)

Do pregnancy-related variables contribute additional predictive validity to an
existing indirect drug screening tool developed with postpartum women (i.e., the
WIDUS)?

3)

Considering both prenatal and general drug use correlates, which items best predict
recent drug use in this sample of pregnant women?

4)

How well do direct measures of drug use predict prenatal drug use (i.e., positive
UDS) compared to indirect measures?

Based on past research, the following hypotheses were made: Hypothesis 1) pregnant women
will underreport recent drug use (i.e., prevalence rates of drug use will be higher according to
urinalysis than direct self-report); Hypothesis 2) indirect screening tools will be a better predictor
of recent drug use according to urine toxicology results than direct screening methods.
Method
Participants
Participants were 231 pregnant women attending a return prenatal appointment at the
VCUHS Women’s Health Clinic. Demographic characteristics for the sample are summarized in
Table 2. Specifically, the sample was primarily African American (66%), single (75%) and 25
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years of age or younger (61%; ages 18-25). The mean estimated gestational age (EGA) for the
fetus, at time of assessment was 26.4 weeks (SD = 9.0), which is the beginning of the third
trimester. Additional pregnancy-related statistics are presented in Table 3.
Table 2
Demographic characteristics N = 231
Variable
Age (years)

n

%

18 - 21
22 - 25
26 - 29
30 - 33
34 - 37
≥ 38

73
67
43
32
12
4

32
29
19
14
5
2

Black or African American
White
More than one race
American Indian or Alaska Native
Hispanic or Latino

152
55
12
8
4

66
24
5
3
2

59

25

181

78

83

36

80
162

35
70

42
183
5

18
80
2

215
15
0

94
6
0

Race/Ethnicity

Marital status
Married
Education
Completed high school or received GED
Employment
Working 20 hours or more per week
Insurance/Support
Have health insurance through an employer
Receive some form of public assistance
Relationship status
None
Yes, with the FoB
Yes, but not with the FoB
Contact with FoB
Yes, current
In the past only
Do not know FoB well
Note. FoB = Father of my baby.
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Table 3
Pregnancy characteristics N = 231
Variables
EGA (weeks)
EGA at pregnancy recognitiona
EGA at first OB appointment
Parity
Primigravida
Total pregnancies (including current)
Live births

Mean (SD) or n
26.35 (9.0)
6.48 (4.2)
9.42 (4.8)

Range or %
2, 40
1, 31
1, 27

67
2.73 (1.9)
1.56 (1.5)

29
1, 8
0, 8

33
52
83
37
25

14
23
36
16
11

Pregnancy intention
Wanted to be pregnant sooner
Wanted to be pregnant then
Wanted to be pregnant later
Did not want to be pregnant then or in future
Do not know

Note. EGA = Estimated gestational age.
a
How many weeks pregnant were you when you first thought you might be pregnant?

Inclusion Criteria: To be eligible for the study, women had to be: at least 18 year of
age, pregnant, and able to understand spoken English. In addition, women had to have completed
at least one prenatal visit in the VCUHS OB clinic prior to study enrollment in order to exclude
women who used drugs without knowledge of their pregnancy.
Exclusion Criteria: Women who were unable to provide informed consent due to
cognitive impairment or a major psychiatric illness were ineligible for the study.
Sampling Procedures
Participants were recruited from the VCUHS Women’s Health Clinic, which provides a
wide variety of obstetric and gynecological services for women in the greater Richmond,
Virginia area. Approximately 90 new obstetric patients are seen in the prenatal care clinics each
month. Women were approached while waiting for their OB appointment in the clinic waiting
room and screened for eligibility (please see Appendix B for Recruitment Script). If a woman
was eligible, she was given a brief explanation of the two-phase project and potential to earn $40
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in gift cards. Study procedures were approved by the VCU Institutional Review Board (protocol
number HM12365) and the NIH NIDA Ethics Committee.
Materials
All study questionnaires, including the WIDUS-P development version, were
administered via computer as opposed to paper-and-pencil or face-to-face interview methods.
Women used headphones to hear each item and the various response options were read aloud as
they appeared on the computer screen. The computerized test battery measures are described
below in the order that they were administered. Order of administration was important for the
generalizability of results and thus the indirect items of drug use had to be completed prior to the
more direct measures of prenatal drug use risk.
Wayne Indirect Drug Use Screener- Pregnancy (WIDUS-P). The WIDUS-P
development version (please see Appendix C), consists of 86 items and contains 64 of the 127
items from the development version of the WIDUS. Items from the WIDUS were selected for
one of two reasons. Forty of the items were chosen because of their superior performance on
selection criteria (e.g., endorsement rates, reading level, association with drug use, participant
and expert ratings) in Dr. Ondersma’s analyses of 400 postpartum women. The item, “I smoked
at least one cigarette during the last month of my pregnancy,” which was a top 40 item, was
changed to “I smoked at least one cigarette the week before I learned I was pregnant” in order to
make it applicable to a pregnant sample. Due to the difference in the nature of the samples (i.e.,
the WIDUS was developed using a sample of post-partum women whereas the current study will
recruit pregnant women), additional items (i.e., 24 from the development version of the WIDUS)
were added to capture domains potentially relevant to a sample of pregnant women. In addition,
based on a review of the literature focused on correlates of drug use during pregnancy (see
section above), additional items were generated to include correlates not already addressed in the
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top 40 WIDUS items or the additional 24 items retained from the WIDUS development version.
Additional items included general pregnancy-related questions, such as estimated gestational age
at first prenatal visit, pregnancy intention (i.e., intended, unwanted, mistimed, or ambivalent;
Mohllajee, Curtis, Morrow, & Marchbanks, 2007), and types of maternal loss experienced (i.e.,
died during birth/stillborn, abortion, death during the first 4 months of pregnancy, death after the
first 4 months of pregnancy).
Drs. Ondersma and Svikis subsequently evaluated each item for its clarity and usefulness
in identifying drug-using pregnant women within the VCUHS OB/Gyn clinic. Considerations
were also made to ensure that items appropriately sampled relevant domains (e.g., exposure to
violence was assessed using several items, rather than a single item), yet did not contribute
unnecessarily to the length of the measure.
Drug CAGE. The drug CAGE is a 4-item measure that asks questions about four
problem domains: annoyance, cutting down, guilt, and eye-opener use. A “yes” response to one
or more items was used to categorize participants as drug-positive according to this measure
(Bradley et al., 2001).
Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST; WHO
ASSIST Working Group, 2002). The ASSIST was developed to detect substance use in
primary and general medical settings. In Dr. Ondersma’s original WIDUS development study,
the first two items of the ASSIST were included in the measure to screen for drug use in the most
direct and parsimonious way possible. These same items were also included in the present study,
as they ask whether participants have ever used marijuana, cocaine, opiates, or amphetamines in
their lifetime as well as during three months prior to pregnancy recognition. The present study
also added a third question which asked specifically about recent (last month) drug use via selfreport.
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Drug Abuse Screening Test (DAST-10; Bohn et al., 1991). The DAST is a widelyused, self-report questionnaire that measures consequences of drug use and other factors
associated with drug use disorders. The cut-off score for the 10-item version is 3 (Skinner, 1982).
The psychometric properties of the DAST have been supported in a number of studies (Yudko et
al., 2007); however, as previously mentioned, the DAST’s utility as a screening tool in
populations vulnerable to social desirability and denial (Skinner, 1982; El-Bassel et al., 1997) is
of concern. Dr. Harvey Skinner provided his permission for use of the DAST in the present
research study.
Urine drug screening (UDS). Urine samples were obtained from all participants who
agreed to participate in Phase 2 of data collection. Cups with embedded test strips on the cap
(i.e., Reditest® RediCup® drug screen, 10 panel), were purchased from Redwood Toxicology
Laboratory, a federally-certified supplier. Screens were performed by the main investigator and
trained research assistants and provided only qualitative data (i.e., positive or negative) on
methamphetamine, cocaine, marijuana, benzodiazepines, methadone, barbiturates, MDMA
(ecstasy), opiates, PCP, and oxycodone use. With the exception of marijuana, urinalysis provides
a window of detection between 24 and 48 hours. Detection of marijuana varies according to the
extent of use; however detection can range from two to 14 days. For the gold standard criterion
of drug use (i.e., urinalysis drug assay), a participant’s drug status was considered “drug
positive” if she screened positive for methamphetamines, cocaine, marijuana, barbiturates,
MDMA and/or PCP. While evidence of benzodiazepine, methadone, opiate and/or oxycodone
use via urinalysis drug testing might also demonstrate prenatal drug use, these categories of drug
were not considered in the construction of the primary drug use variable because the positive
screen could be the result of prescription (i.e., licit) use of these substances.
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Design and Procedures
The primary goal of the study was measurement development and validation. A critical
design component of this research, intended to protect the validity of findings, was that
participation was completely anonymous. Participants were not required to provide their name or
other identifying information to participate in the study (i.e., they were not required to sign a
consent form). Such anonymity was important as it may have minimized the fear of negative
consequences and stigma associated with self-reporting drug use or providing a positive urine
sample. Consequently, anonymity may have encouraged greater rates of participation and more
accurate responses on both indirect items and direct measures of drug use.
Another important design consideration involved the use of sequential informed consent
to protect the generalizability of the WIDUS-P. Generalizability depends on how closely future
clinical applications of the WIDUS for pregnant women can be replicated. This meant that
participants must not have initially known that they would be asked for permission to drug test
their urine. If women were aware of the possibility of drug screening while answering questions,
they may have responded differently than if they had no knowledge of the potential to be tested.
In this situation, altered responding would have limited the use of the WIDUS in settings where
drug does not routinely occur (e.g., prenatal care clinics). Therefore, a two phase consent
procedure allowed for initial withholding of information necessary for valid measure
development. Participants completed Phase 1, which involved completion of the computerized
battery, before they learned about the existence of Phase 2 (collection of a urine sample). This
procedure was critical to preserve the external validity of the WIDUS-P.
Phase 1 procedures. Phase 1 concerned the administration of the computerized battery.
Due to issues of validity previously mentioned, information about urine drug testing was
withheld until after the participant completed the computerized battery. When a woman
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expressed interest in the study, she was asked to come to the research space adjacent to the 6th
floor Women’s Health clinic after her prenatal appointment. Once she arrived there, a research
staff member informed her of study details (please see Appendix D, “Information Sheet #1”),
including what kinds of questions will be asked, her rights as a participant, the anonymous and
voluntary nature of the project (i.e., she will not be asked to give her name), her compensation
for completing phase 1of a $20 gift card, and that phase 2 will be described to her after she has
completed phase 1. Participants were assured that their information would not be shared with
clinic staff. After the woman provided verbal consent to participate, the researcher introduced
her to the tablet PC, instructed her to put on headphones, and begin the computer program.
Headphones were used in order to protect participants’ privacy and to circumvent issues of
literacy. The computer program, via an animated character (i.e., Peedy the parrot), instructed the
participant how to use the computer and answer questions, and then introduced the questionnaire.
Previous research utilizing this software and animated character has shown that women (N =
+1000) found it easy to use and likeable (e.g., Ondersma, Chase, Svikis, & Schuster, 2005).
Once the participant answered all computer questions, the program prompted the participant to
tell the researcher she was finished. The researcher then entered an identification number for the
participant so that the data could be linked to her urinalysis results. After the computerized
assessment was complete, the research assistant gave the participant a $20 gift card. Total
administration time for phase 1 was 20-25 minutes.
Phase 2 procedures. After providing compensation for phase 1, the researcher described
phase 2 to the participant (please see Appendix E “Information Sheet #2”). She was told that the
second phase involved unsupervised collection of a urine sample and that she would be
compensated with a second $20 gift card. If the woman agreed to participate, the researcher took
the participant to the public restroom located in the adjacent hallway, informed her that a urine
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cup was located in the metal cabinet behind the door and instructed her to place the cup back in
the cabinet once she provided the sample. After the participant left the restroom, the researcher
gave her another $20 gift card and an information sheet (see Appendix F “Information Sheet
#3”) that debriefed her on why Phase 1 and 2 were conducted separately and thanked her for
participating. Once she left, the staff member entered the research office adjacent to the
bathroom, retrieved the urine sample from the cabinet and assayed the sample for drugs using the
test cup. Test results were recorded, along with the participant’s identification number, and then
the test strip was wrapped in paper towel and disposed of in a waste basket.
Data Analysis Plan
In order to maintain consistency with procedures used to develop the original WIDUS
and to allow for comparison, the present study used data analytic procedures similar to those
employed in Dr. Ondersma’s R21 NIDA grant. Specifically, this included randomly dividing the
sample into a training sample (n = 131) and a validation sample (n = 100) in order to develop and
validate indirect measures. In addition, a similar multi-step strategy (described below) was used
to reduce the initial item pool and evaluate the predictive validity of these indirect measures.
Research question 1. The first research question asked whether women in this sample
minimized or denied prenatal drug use and if so, to what extent did self-report differ from UDS
results. Hypothesis 1 predicted that rates of drug use by urinalysis drug assay would be greater
than rates by self-report. To test this hypothesis, rates of self-reported past month drug use and
positive drug status were compared.
Research question 2. The second research question asked whether pregnancy variables
contributed additional predictive validity to the WIDUS. Forty-five pregnancy items were
evaluated. The item, “how many weeks pregnant are you” was used as demographic data. To
address this question, we reduced the number of variables predictive of positive drug status using
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a three-step process with the training sample (n=131). This process included removing items
based on:
1) Exclusionary criteria. Frequencies of positive endorsement and Flesch-Kincaid
ratings of reading grade level were determined for each item. Items were removed
based on poor endorsement (i.e., endorsement less than 10%) and high reading levels
(i.e., Flesch-Kincaid rating higher than a 9th grade reading level).
2) Univariate relationship with drug status. Each remaining variable’s univariate
association with urine toxicology results was then examined by performing a chisquare test for independence. A total of 13 variables (12 items with the largest chisquare value plus the plus the total score for the original WIDUS) were chosen for
inclusion in the next step based on the recommended 10:1 events per variable ratio in
logistic regression analysis (Peduzzi, Concato, Kemper, Holfond, & Feinstein, 1996)
and given the training sample size of 131.
3) Multivariate relationship with drug status. In this step, hierarchical logistical
regression was used to examine the multivariate relationship between these 12
variables and drug status, above and beyond the WIDUS. Participants’ drug status
was entered as the criterion variable, the WIDUS was entered at block 1 and the 12
pregnancy variables were entered at block 2. Subsequent hierarchical logistical
regressions were performed to determine the final item(s) to be included.
Following this process, ROC curve analyses were conducted to determine the predictive validity
of adding the pregnancy item(s) identified in step three to the WIDUS. A ROC curve plots the
rate of true positives (sensitivity) against the false positive rate (1- specificity) for different
possible cutoff scores of a test. The more closely the curve follows the left-hand and top borders,
the more accurate the measure. Area under the curve (AUC) is the likelihood that any given
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positive case will score higher than a given negative case on the screening tool and is commonly
used as a summary measure of classification accuracy. An AUC of .50 signifies that the
screening tool is accurately classifying positive cases at a rate equivalent to chance (Swets,
1988). Sensitivity (the percentage of women with a positive urine screen who are also identified
as at-risk by the screener) and specificity (the percentage of women with a negative urine screen
who are also identified as not at-risk by the screener) for this new measure were calculated.
Given the primary goal of this measure was to identify women who used drugs during
pregnancy, sensitivity was valued over specificity in determining a cut-off score. Sensitivity was
also prioritized because of the small consequences of false positives; it is be more desirable for a
non-drug using woman to screen positive and receive intervention than for a drug-using woman
to screen negatively and miss intervention. Positive predictive value (i.e., the percentage of
women who are positive on the screener who also have a positive toxicology screen), negative
predictive value (i.e., the percentage of women who are negative on the screener who also have a
negative toxicology screen) and percent correctly classified were also calculated for the measure
at the optimal cut-off score.
Cross-validation. The addition of the pregnancy item(s) to the WIDUS was crossvalidated in the validation sample (n=100) using hierarchical logistic regression, ROC curve
analysis, and other statistics (positive predictive value, negative predictive value, and
classification accuracy).
Research question 3. The third research question asked which indirect items, including
both general and pregnancy variables, best predicted recent drug use. Three demographic items
(i.e., age, ethnic background and EGA) were not included, reducing the total number of indirect
items evaluated to 83. To determine which items should be included in the pregnancy screener
(i.e., the Wayne Indirect Drug Use Screener- Pregnancy; WIDUS-P), the same three-step
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procedure used in question 2 was applied to data from the training sample and used to reduce the
number of items to a 4-7 item measure. This process included removing items based on:
1) Exclusionary criteria. Frequencies of positive endorsement and Flesch-Kincaid
ratings of reading grade level were calculated for each item. Items were removed
based on poor endorsement (i.e., endorsement less than 10%), high reading levels
(i.e., Flesch-Kincaid rating higher than a 9th grade reading level), highly stigmatizing
content (e.g., abuse, violence, involvement with police) and direct alcohol and illicit
drug content (e.g., family history of drug or alcohol problems, marijuana use by
friends or partner).
2) Univariate relationship with drug status. Chi-square tests of independence were
calculated for all remaining variables to evaluate their univariate association with
urine toxicology results. Thirteen variables were chosen for inclusion in the next step
based on previously mentioned N:k ratio recommendation.
3) Multivariate relationship with drug status. In Step 3, we performed a series of
logistic regression analyses to assess each of the 13 variables’ multivariate
association with drug status in order to further reduce the item count. In the first
logistic regression, items with a p-value greater than .5 were eliminated. Additional
logistic regression analyses were performed to remove items with lower odds ratios
and higher levels of significance. The primary consideration in retaining items was
the size of their association with drug status, rather than significance. The remaining
items were combined to form the WIDUS-P.
ROC curve analysis was conducted to determine the predictive validity of the WIDUS-P and an
optimal cut-off score. PPV, NPV and percent correctly classified were also calculated for the
determined cut-off score.
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Cross validation. The WIDUS-P was then cross-validated on the validation sample (n=
100) using logistic regression and ROC curve analyses. Other statistics of predictive validity
(PVV, NPV and classification accuracy) were also calculated. To supplement these crossvalidation analyses, we selected five random samples of 100 participants (among the total
sample, N=231) and calculated AUC, sensitivity, specificity, PPV, NPV and classification
accuracy to further examine the validity of the WIDUS-P.
Finally, we performed two hierarchical logistic regression analyses in order to compare
the WIDUS-P to the WIDUS. For both analyses, participants’ drug status was entered as the
criterion variable. For the first analysis, the WIDUS was entered at block 1 and the WIDUS-P
was entered at block 2. The reverse was entered for the second logistic regression analysis.
Research question 4. Given the frequent use of direct screening tools to identify at-risk
drug use, the fourth research question examined the predictive validity of these methods
compared to that of indirect methods (i.e., the WIDUS, WIDUS-P and the additional indirect
measure adapted in questions two). The second hypothesis predicted that indirect screening tools
would be a better predictor of recent drug use than direct screening methods. To evaluate this
hypothesis, sensitivity for each direct screening method (i.e., the DAST, Drug CAGE, and single
questions of lifetime, pre-pregnancy and past month drug use) was calculated and compared to
the sensitivity of indirect methods. Specificity, PPV, NPV and classification accuracy were also
determined for all methods to provide additional comparison.
Results
Recruitment
Study recruitment took place between May 28, 2010 and May 31, 2011. While it is likely
that women were screened eligible on multiple occasions (due to attending multiple OB visits
during the recruitment period) and thus this number is likely an overestimation, 1571 women
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were eligible for study participation. Of these women, N=245 (16%) pregnant women provided
informed consent and completed Phase 1 (computerized assessment). Of these, N=231 (94%)
also completed Phase 2 (provided urine sample for drug assay). For the n=14 women who
began phase 1, reasons given for not continuing study participation included: not having enough
time (n = 6), not being able to urinate (n = 4) and being too tired (n = 1). An additional three
women did not provide an explanation for their decision. One woman provided consent but did
not provide any data, thus only 13 women completed phase 1. Descriptive data from these noncompleters (i.e., completed phase 1 only) are presented in Table 4 as a comparison to data from
participants who completed both phases of the study (i.e., participants who also provided a urine
sample). None of the non-completers self-reported recent (i.e., past month) drug use, compared
to 5% of study completers (11 of 231 women).
Recoding of Variables
Several variables were re-coded or computed prior to data analysis to adjust for their
association with drug status. A value of “1” was assigned to the response consistent with the
variable’s predicted direction of association with drug use. For the item concerning pregnancy
intention, responses of “I wanted to be pregnant later,” “I didn’t want to be pregnant then or at
any time in the future,” and “I don’t know” (i.e., unintended pregnancy) were coded as “1” and
responses of “I wanted to be pregnant sooner” and “I wanted to be pregnant then” (i.e., intended
pregnancy) were coded as “0”. Relationship status was re-coded so that “I am not in a
relationship” signified “1.” Although the item regarding amount of contact with the father of the
baby was originally categorical, with three response options, one response (“I don’t know the
father of this baby that well”) was never endorsed. Instead, the variable was re-coded into
current contact (coded “0”) and past contact only (coded “1”). In addition, continuous variables
concerning prenatal characteristics were dichotomized according to cut-offs identified by quartile
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frequencies and the variable’s hypothesized relationship with drug status. For instance, the item,
“how many weeks pregnant were you when you first thought you might be pregnant,” was coded
positive if the participant responded 4 or more weeks (82% of the sample). The items concerning
number of weeks pregnant at first OB appointment (6 weeks or more coded as “1”; 83% of
sample endorsed this response) and number of pregnancies (multigravida coded as “1”; 71% of
the sample endorsed this response) were also dichotomized. Finally, several variables were
reverse-coded to account for their direction of association with drug status. For example, being
unmarried has been shown to be significantly associated with prenatal drug use (El Marroun et
al., 2008) so the item, “I am currently married,” was reverse-scored. Other recoded items were “I
graduated from high school or completed my GED,” “I am currently working 20 hours or more
per week,” “I currently have health insurance through an employer,” “I almost always use
condoms during sex,” and “I am currently in a relationship.”
Item Endorsement
Rates of positive endorsement for indirect items ranged from 2% to 72%. Table 3
presents the rate of positive endorsement for each dichotomous item in the full sample (N = 231)
in order from most to least commonly endorsed. Frequencies for the reverse-coded items
(symbolized with an asterisk in Table 4), rather than for the original item, are presented in this
table (e.g., 65% of participants do not currently have health insurance through an employer).
Categorical and continuous pregnancy variables were previously described in Tables 2 and 3,
respectively.
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Table 4
WIDUS-P Item Responses
# Type
11
7

G
P

6

G

10
5
12
54
21
58

P
G
G
G
G
G

22

P

34

G

61
8

G
P

19
33

G
P

46
47
64
16

P
P
P
G

20
37

G
P

41

P

85
15
18
32

P
G
G
G

14
51
17

G
G
G

65

G

Item

I often eat fast food and/or junk food
I currently receive some form of public assistance, such as food
stamps, WIC, Medicaid, SSI or TANF
*I currently have health insurance through an employer, either
mine or a family member’s
*I almost always use condoms during sex
*I am currently working less than 20 hrs per week
I have been treated at an emergency room in the past year
I get bored easily
Most of my friends think marijuana is no big deal
At least one person in my immediate family (parent, brother, or
sister) has had problems with depression
I have at least one caffeinate beverage (for example, caffeinated
soda, coffee, or energy drink) every day
There have been times in my life, for at least two weeks straight,
where it felt like everything was an effort
I am easily upset about things
At least once in my life, I have been diagnosed with a STD, such as
gonorrhea, Chlamydia, Herpes, syphilis, HIV, or any other STI
Most of my friends smoke cigarettes
There have been times in my life, for at least two weeks straight,
where I felt so down or depressed that nothing could cheer me up
It’s hard to get places because of transportation
In the past 12 months, I’ve worried about my housing situation
Over the past month, I have felt down, depressed, or helpless
I was a daily smoker during the year before I learned I was
pregnant
At least two of my closest friends use marijuana
One or more of my biological parents have had a problem with
drugs or alcohol
In my lifetime, I have been hit, slapped, kicked or otherwise
physically hurt by someone
The father of this baby currently smokes cigarettes
I have smoked at least 100 cigarettes in my entire life
I’m often around second hand cigarette smoke
There have been times in my life, for at least two weeks straight,
where I felt completely hopeless about things
In the past year, I have been bothered by pain in my teeth or mouth
I get mad easily and feel a need to blow off some steam
I smoked at least one cigarette the week before I learned I was
pregnant
Drugs are everywhere in my neighborhood
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% Yes
N= 231 n =13a
72
70
70
62
65

62

65
64
63
63
62
59

62
54
54
54
54
62

58

69

57

69

52
51

23
70

49
49

46
39

48
48
48
47

39
15
23
39

47
47

39
54

47

23

47
46
46
45

39
46
31
46

44
44
43

31
23
46

43

31

31

G

53
57
86
36

G
G
P
G

66
67

G
P

68

P

69
63

G
G

24

P

23

P

42

P

50
38

G
G

60

G

39

G

3
25

G
P

40
26

G
P

48
80

P
P

4
13
45

G
G
P

82
30

P
P

71
49

G
P

There have been times in my life, for at least two weeks straight,
where I felt completely worthless
I feel overwhelmed by my life and my problems
I experience “flashbacks” of bad things that have happened to me
The father of this baby thinks marijuana is no big deal
As an adult, I have seen somebody get stabbed, shot, or seriously
beaten
I often have trouble sleeping (not counting during pregnancy)
I feel very overwhelmed when thinking about taking care of a new
baby
I have repeated and disturbing memories of a stressful thing that
happened to me
I lose my temper very easily
I have seen or experienced worse things than most other people
have
When I was a child, I saw someone get stabbed, shot, or seriously
beaten
When I was a child, I saw adults in my home physically hurting
each other
There have been times in my life I have not felt safe around my
current partner or past partner
Things have usually gone against me in life
One or more of my brothers or sisters has had a problem with
drugs or alcohol
In elementary school, I often got into trouble with teachers or the
principal because of my behavior (fighting, talking in class, or
coming to class late)
I have been abandoned by someone I love more than most people
have
*I am currently married
When I was a child, an adult hit me hard enough to cause bleeding,
bruises, or welts
I have been in trouble with the police
When I was a child, an adult touched my private parts in a sexual
manner, or got me to touch their private parts in a sexual manner
I often move from place to place
Have you ever had a pregnancy that ended during the first 4
months (not including an abortion)?
*I graduated from high school or completed my GED
I have missing teeth
In the past year, I’ve gone hungry because I didn’t have enough
money to buy food
Have you ever had an abortion?
Since my sixteenth birthday, I have been injured in an assault or
fight (not counting during sports)
I often feel empty inside
In the past year, the police have been called to my home because of
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39

31

38
38
36
35

15
31
39
23

34
34

31
31

33

31

33
31

23
15

30

15

28

23

28

8

28
27

8
31

27

8

26

15

25
25

8
8

25
24

8
8

23
23

0
15

22
22
22

15
23
0

22
21

23
15

21
20

0
0

27
43

P
P

52
72
70
55
28

P
P
P
G
P

35
62

G
G

56

P

44

P

81

P

79
84
59
29
9

P
P
P
P
P

a fight or argument
When I was a child, I saw people using drugs in my home
Within the last year, I have been hit, slapped, kicked or otherwise
physically hurt by someone
Some of my immediate family members are pretty violent
In the past, I have attempted to hurt myself
In the past, I have told someone I was going to hurt myself
I live life on the edge
Since my sixteenth birthday, I have had fractures or dislocations to
my bones or joints
As an adult, I have been badly beaten up at least once
When I was younger than 13 years old, I often stayed out past
midnight
I have conflict with people in authority, like teachers, supervisors,
and the police
During my current pregnancy, I have been hit, slapped, kicked or
otherwise physically hurt by someone
Have you ever had a pregnancy that ended after 4 months but
before birth?
Have you ever had a baby that died during birth or was stillborn?
Current contact with father of this baby
I sometimes do really harmful things to myself
Since my sixteenth birthday, I have injured my head
I have been diagnosed with Hepatitis C

19
19

8
8

17
17
16
14
12

0
23
31
8
8

12
11

8
0

10

0

8

8

8

8

7
7
5
4
2

8
0
0
0
0

Note. * = Item was changed from original item to reflect reverse-coding; G = general item. P = pregnancy item. Item
responses were true/false or yes/no.
a
13 women consented for study participation but did not complete phase 2.

Prenatal Drug Use
Prevalence of drug use. Rates of drug use varied by type of report (i.e., self-report
versus urine drug screening) and time frame. Urinalysis documented higher rates of recent drug
use than self-report. Forty-three participants (19%) tested positive for at least one drug. When
drugs that could have been consumed with a prescription (i.e., benzodiazepines, methadone,
opiates and oxycodone) were excluded from analyses, the rate decreased to 16% (n = 36). Note,
this prevalence rate and not the abovementioned rate is used to describe recent drug use by UDS
for the remainder of the study. Among self-reported drug use, prevalence of lifetime drug use
was the highest (39%, n = 90), followed by use during the 3 months prior to pregnancy (20%, n
= 46) and lastly, past month drug use (5%, n = 11). Interestingly, in response to question #1 on
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the DAST, only 19% (n = 43) of participants reported using drugs “other than those required for
medical reasons” in the past 12 months. This difference highlights the inconsistency in selfreported drug use: 20% reported using in the three months prior to pregnancy, but only 19%
reported using in the past year.
Type of drug use. The most commonly used drug, according to urinalysis, was
marijuana. Among the total sample, 15% (n = 34) of participants tested positive for marijuana. A
much smaller percentage tested positive for methadone (1.7%, n = 4), opiates (1.7%, n = 4),
oxycodone (1.3%, n = 3), cocaine (0.9%, n = 2), methamphetamines (0.4%; n = 1), and
barbiturates (0.4%, n = 1). Benzodiazepines, MDMA, and PCP were not recently used by
pregnant women in this sample. Table 5 describes the type of drug use by participants coded as
“drug positive.” Most drug-using women tested positive for marijuana only (89%).
Table 5
Type of Drug Use among “Drug Positive” Participants, n = 36
Type
n
Marijuana
32
Marijuana and cocaine
1
Marijuana and methamphetamine
1
Cocaine
1
Barbiturates
1
Research question 1: Self-reported drug use versus UDS.
In support of Hypothesis 1, the rate of drug use by urinalysis (16%, n = 36) was three
times higher than the rate by self-report (5%, n =11). Two-thirds of the women who tested
positive (67%, n = 15) denied using in the past month.
Research Question 2: Predictive Validity of Pregnancy Variables
Step 1: Exclusionary criteria. Fifteen items were removed for under endorsement (i.e.,
< 10%) and high reading levels (i.e., if they required a 9th grade reading level or higher according
to Flesch-Kincaid ratings), reducing the item count to 30. In addition, the item, “How many of
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these pregnancies ended in the birth of a live baby” was removed because it was dependent on a
previous item and could be not evaluated independently.
Step 2: Univariate relationship with drug status. The twelve items with the largest chisquare value were retained (values ranged from 2.93 to 10.27).
Step 3: Multivariate relationship with drug status. Of the 12 variables entered into the
hierarchical logistic regression in block 2 (block 1 = WIDUS), three items with the lowest pvalue (p < .35) and highest odds ratio (Exp(B) > 2) were retained: abortion (Exp(B) = 3.38, p =
.046 ), assistance (Exp(B) = 2.939, p = .23) and housing (Exp(B) = 2.08, p = .31). Hierarchical
logistic regression was repeated with only the abortion, assistance and housing items entered at
block 2. Table 6 presents the odds ratios and significance of each predictor in this model and
shows that the abortion variable was the only one to retain significance. The addition of these
variables at block 2 was statistically significant, χ2(3) = 10.61, p = .014, and increased the rate of
correction classification from 77% to 83%.
Table 6
Summary of Hierarchical Logistic Regression Analysis for WIDUS + Pregnancy Variables Block
2 (N = 131)
Variable
Sig.
OR
95% CI
WIDUS
.02
1.55
[1.06, 2.28]
Abortion
.02
3.40
[1.17, 9.84]
Housing
.14
2.44
[.75, 7.99]
Assistance
.17
3.11
[.62, 15.67]
Note. Sig. = p-value; OR = odds ratio; CI = confidence interval; Abortion = Have you ever had an abortion;
Assistance = I currently receive some form of public assistance, such as food stamps, WIC, Medicaid, SSI, or
TANF; Housing = In the past 12 months, I’ve worried about my housing situation.

Next, we examined the addition of the abortion item to the WIDUS. In a hierarchical
logistic regression analysis, the WIDUS was entered at block 1 and the abortion item was entered
at block 2. Odds ratios for the WIDUS and abortion item are reported in Table 7. The abortion
item added significant additional variance to the WIDUS, χ2(3) = 6.06, p = .01. The effect size of
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adding abortion to the WIDUS was small, with Cox and Snell R-square = .15 and Nagelkerke Rsquare = .24.
Table 7
Summary of Hierarchical Logistic Regression Analysis for WIDUS + Abortion Block 2 (N =
131)
Variable
Sig.
OR
95% CI
WIDUS
<.001
1.91
[1.35, 2.69]
Abortion
.014
3.75
[1.31, 10.71]
Note. Sig. = p-value; OR = odds ratio; CI = confidence interval; Abortion = Have you ever had an abortion.

The ROC curve for the WIDUS+abortion showed an AUC of .77 (standard error = .045,
p < .001, 95% CI = .68, .85), indicating that there is a 77% likelihood that a randomly selected
woman with a positive UDS will have a higher WIDUS+abortion score than a randomly selected
woman with a negative UDS. This is a slight improvement in classification accuracy from the
WIDUS (AUC = .74, standard error = .05, p < .001, 95% CI = .65, .84). ROC curve analysis
indicated that a cut-off score of 4 optimized sensitivity (.81). Specificity was .57. At this cutoff
score, the measure’s positive predictive value (i.e., the percentage of women who are positive on
the WIDUS+abortion who also have a positive toxicology screen) was .32 and negative
predictive value (i.e., the percentage of women who are negative on the WIDUS+abortion who
also have a negative toxicology screen) was .92. Overall, the WIDUS+abortion, with a cutoff
score of 4, correctly classified 71% of cases.
Cross-validation. When the hierarchical logistic regression (block 1 = WIDUS, block 2 =
abortion) was repeated, the abortion item did not significantly predict drug status above and
beyond the WIDUS, χ2(1) = 2.22, p = .14; however the effect of the variable still maintained its
magnitude (OR = 3.0, p = .13, 95% CI = .724, 12.41). Using a cut-off score of four, sensitivity
was high (.80) with moderate specificity (.66). The positive predictive value was .21, while the
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negative predictive value was .97. Overall, the WIDUS plus the abortion item correctly classified
76% of participants.
Research Question 3: Predictive Validity of Indirect Items within a Pregnant Sample
Step 1: Exclusionary criteria. Nineteen items were removed for under endorsement (i.e.,
< 10%), high reading levels (i.e., Flesch-Kincaid 9th grade reading level rating or higher), highly
stigmatizing content (e.g., abuse, violence, involvement with police) and direct alcohol and illicit
drug content (e.g., family history of drug or alcohol problems, marijuana use by friends or
partner) were eliminated. This step removed 19 items, reducing the item count to 64.
Step 2: Univariate relationship with drug status. The 13 items with the largest chisquare value were retained (values ranged from 4.82 to 15.99) and included in step three.
Step 3: Multivariate relationship with drug status. In the first logistic regression, items
with a p-value greater than .5 were eliminated, removing five of the 13 items. Table 8 shows the
subsequent two logistic regression analyses. In the eight predictor model, the upset and friends
cigarettes items were removed because of their lower odds ratio and higher level of significance
in comparison to the other six items. This resulted in the six predictor model. As seen in Table 8,
these six items were strongly associated with drug status (odds ratios range from 2.82 to 16.85)
and therefore were retained. As previously mentioned, the primary consideration for retaining
these items was the size of their association with drug status, rather than significance.
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Table 8
Summary of Logistic Regression Analyses in the Training Sample
Variable
Sig.
OR
95% CI
Eight Predictorsa
Midnight
.002
15.58
[2.65, 91.68]
Abortion
.008
6.18
[1.61, 23.77]
100 cigarettes
.012
6.86
[1.53, 30.80]
Pain
.015
5.34
[1.39, 20.52]
Seen worse
.086
2.74
[.87, 8.69]
Hours
.139
2.98
[.70, 12.67]
Upset
.270
2.08
[.57, 7.59]
Friends cigarettes
.691
0.76
[.19, 2.98]
Six Predictorsb
Midnight
.001
16.85
[3.06, 92.76]
Abortion
.011
5.45
[1.47, 20.13]
100 cigarettes
.008
6.37
[1.61, 25.19]
Pain
.016
5.06
[1.36, 18.87]
Seen worse
.079
2.82
[.89, 8.96]
Hours
.120
3.03
[.75, 12.22]
Note. Sig. = p-value; OR = odds ratio; CI = confidence interval; 100 cigarettes = I have smoked at least 100
cigarettes in my entire lifetime; Abortion = Have you ever had an abortion; Friends cigarettes = Most of my friends
smoke cigarettes; Hours = I currently work less than 20 hours per week; Midnight = When I was younger than 13
years old, I often stayed out past midnight; Pain = In the past year, I have been bothered by pain in my teeth or
mouth; Seen worse = I have seen or experienced worse things than most other people have; Upset = I am easily
upset about things.
a
Logistic regression model with eight predictors.
b
Logistic regression model with six predictors.

The six indirect items listed in Table 8 were combined to form the WIDUS-Pregnancy
(WIDUS-P). The ROC curve for the WIDUS-P is presented in Figure 1 and shows an AUC of
.87 (standard error = .036, p < .001, 95% CI = .80, .94), indicating that there is an 87%
likelihood that a randomly selected woman with a positive UDS will have a higher WIDUS-P
score than a randomly selected woman with a negative UDS. Said another way, the WIDUS-P
demonstrated good accuracy in classifying women who tested positive for recent drug use.
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Figure 1. ROC curve for the six-item WIDUS-P measure predicting prenatal drug use in the
training sample. Diagonal line represents chance prediction. AUC = .87.
Table 9 lists the sensitivity and specificity for each possible cut-off score and also
displays the dramatic changes in sensitivity and specificity associated with a change in cut-off
score. Given the primary consideration of sensitivity, the optimal cut-off score was three
(sensitivity = .89). At this cutoff score, the measure’s positive predictive value (i.e., the
percentage of women who are positive on the WIDUS-P who also have a positive toxicology
screen) was .40 and negative predictive value (i.e., the percentage of women who are negative on
the WIDUS-P who also have a negative toxicology screen) was .96. Overall, the WIDUS-P, with
a cutoff score of 3, correctly classified 70.8% of cases.
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Table 9
WIDUS-P Cutoff Score Sensitivity and Specificity N= 131
WIDUS-P score
Sensitivity
Specificity
positive if greater
than or equal to:
1
1.00
.14
2
1.00
.39
3
.89
.66
4
.62
.91
5
.19
.99
6
.08
1.00

% Positive
89
68
45
19
4.6
1.5

Note. WIDUS-P score = sum of 6 items rated from 0 to 1.

Cross-validation procedures and analyses. The 6-item WIDUS-P was then crossvalidated on the validation sample (N = 100). Scores on the WIDUS-P were reasonably welldistributed (mean = 2.28, SD = 1.39, skewness = .21, kurtosis = -.41) and yielded an AUC of .85
(standard error = .05, p < .001; see Figure 2), only a slight decrease from an AUC of .87 in the
training sample. The 95% confidence interval for the AUC was .76 to .94. Although scores on
the WIDUS-P were generally well-distributed, positive cases were more common with higher
scores (with the exception of a score of 6; see Table 10), resulting in an irregularly shaped curve.
As shown in Table 11, there was an improvement in sensitivity and specificity for a cut-off score
of 3 in the validation sample (.90 and .74, respectively). Similar to the ROC curve for the
training sample, the ROC curve for the validation sample showed dramatic changes in sensitivity
and specificity associated with changes in cut-off score steps. The positive predictive value of
the WIDUS-P decreased to .28, which meant that 28% of participants who had a positive
WIDUS-P score tested positive for drug use. The negative predictive value was .99.
Classification accuracy improved from 70.8% in the training sample to 76% in the validation
sample.
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Figure 2. ROC curve for the six-item WIDUS-P measure predicting prenatal drug use in the
validation sample. Diagonal line represents chance prediction. AUC = .85.
Table 10
Percent of Drug Positive Participants as a Function of WIDUS-P score
WIDUS-P score
% testing positive
N
0
0%
13
1
0%
25
2
3.3%
30
3
27%
15
4
30%
10
5
29%
7
6
0
Note. n = 100.

Table 11
WIDUS Cutoff Score Sensitivity and Specificity n = 100
WIDUS-P score
Sensitivity
Specificity
positive if greater
than or equal to:
1
1.00
.14
2
1.00
.42
3
.90
.74
4
.50
.87
5
.20
.94
6
.00
1.00
Note. WIDUS-P score = sum of 6 items rated from 0 to 1.
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A logistic regression was performed to determine how strongly the six items that
comprised the WIDUS-P predicted drug status. Results are shown in Table 12. All items, with
the exception of the hours item, performed in the predicted direction (i.e., increased the odds of
testing positive for recent prenatal drug use).
Table 12
Summary of Logistic Regression Analyses in the Validation Sample
Variable
Sig.
OR
95% CI
Midnight
.09
5.43
[0.79, 37.52]
Abortion
.02
10.37
[1.50, 71.83]
100 cigarettes
.26
2.67
[0.49, 14.58]
Pain
.23
0.32
[0.05, 2.02]
Seen worse
.02
11.05
[1.56, 78.52]
Hours
.71
1.50
[0.18, 12.11]
Note. Sig. = p-value; OR = odds ratio; CI = confidence interval; 100 cigarettes = I have smoked at least 100
cigarettes in my entire lifetime; Abortion = Have you ever had an abortion; Friends cigarettes = Most of my friends
smoke cigarettes; Hours = I currently work less than 20 hours per week; Midnight = When I was younger than 13
years old, I often stayed out past midnight; Pain = In the past year, I have been bothered by pain in my teeth or
mouth; Seen worse = I have seen or experienced worse things than most other people have; Upset = I am easily
upset about things.

Additional cross-validation procedures. Table 13 presents data from ROC curve
analyses of five random samples (from the full sample) of 100 participants: the WIDUS-P (cutoff score = 3), on average, maintained good classification accuracy (AUC = .86), sensitivity (.88)
and specificity (.69).
Table 13
Cross-validation of the WIDUS-P (cutoff score = 3) in Five Randomly Selected Samples
Sample
AUC (SE)*
Sensitivity Specificity
PPV
NPV
Classification
Accuracy
1
.88 (.04)
.95
.64
.38
.98
70%
2
.90 (.04)
.94
.74
.41
.98
77%
3
.84 (.05)
.87
.67
.32
.97
70%
4
.89 (.04)
.93
.73
.38
.98
76%
5
.79 (.06)
.73
.66
.28
.93
67%
Average
.86
.88
.69
.35
.97
72%
Note. N = 100; AUC = area under the curve; SE = standard error.
* p < .001.
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WIDUS-P versus WIDUS. Table 14 describes the results of a hierarchical logistic
regression examining the effect of WIDUS-P on drug status, after controlling for the WIDUS. As
shown, the WIDUS-P was a significant predictor of drug status after controlling for the effect of
the WIDUS (χ2(1) = 6.05, p < .05). Table 15 shows the reverse: the effect of WIDUS on drug
status after controlling for the WIDUS-P. Unlike the results of previous analysis, the WIDUS
was not a significant predictor of drug status above and beyond the WIDUS-P (χ2(1) = .003, p >
.05). Although both measures were significant predictors of drug status when compared alone to
the constant-only model (as shown in Block 1 of Table 14 and 15), only the WIDUS-P offered
significant additional predictive validity.
Table 14
Effect of the WIDUS-P on Drug Status, Controlling for the WIDUS
Variable
Sig.
OR
95% CI
a
Block 1
WIDUS
.01
1.82
[1.13, 2.93]
b
Block 2
WIDUS
.96
1.02
[.52, 2.00]
WIDUS-P
.02
2.54
[1.16, 5.14]
Note. N = 100. Sig. = p-value; OR = odds ratio; CI = confidence interval.
a 2
χ (1) = 7.30, p < .01.
b 2
χ (1) = 6.05, p < .05.

Table 15
Effect of the WIDUS on Drug Status, Controlling for the WIDUS-P
Variable
Sig.
OR
95% CI
Block 1a
WIDUS-P
.001
2.48
[1.44, 4.28]
Block 2b
WIDUS-P
.02
2.45
[1.16, 5.14]
WIDUS
.96
1.02
[.52, 2.00]
Note. N = 100. Sig. = p-value; OR = odds ratio; CI = confidence interval.
a 2
χ (1) = 13.35, p < .001.
b 2
χ (1) = .003, p > .05.
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Research Question 4: Direct versus Indirect Measures of Prenatal Drug Use
Sensitivity, specificity, PPV, NPV and classification accuracy for the standardized
measures, the DAST and Drug CAGE, single questions of lifetime, pre-pregnancy and past
month drug use, and the indirect methods (WIDUS, WIDUS+abortion, WIDUS-P) are presented
in Table X. As predicted in Hypothesis 2, the indirect measures outperformed all direct measures
of prenatal drug use with regard to sensitivity. The WIDUS and the WIDUS-P identified almost
90% of all drug users; however, the WIDUS-P was a more specific measure. The
WIDUS+abortion was less sensitive, but still identified more drug-users than direct methods.
Among the direct methods, the DAST, with a cutoff score of one, identified the highest
percentage of prenatal drug users (72%) and also demonstrated good specificity (.76). Using a
higher cutoff score for both the DAST and Drug CAGE resulted in higher specificity, but it
reduced sensitivity by almost half. Sensitivity of the direct questions increased as the time period
in question became more remote; the inverse relationship was observed for specificity. Asking
participants if they used drugs in the past month correctly identified the greatest number of
participants (91%); however, this question only identified 34% of drug users.
In addition, Table 16 reports the percentage of participants who screened positive on a
measure (based on the cut-off score reported in parentheses) or positively endorsed a question.
Based on comparison of self-reported last month drug use to the DAST and Drug CAGE scores,
women appear more willing to disclose drug use consequences (32% for both measures) than
admit to recent drug use (5%).

57

Table 16
Accuracy of indirect and direct screening tools in identifying prenatal drug use, N = 231
Screening Method
Sensitivity Specificity PPV NPV Classification % Positive
Accuracy
a
WIDUS-P (3)
.90
.74
.28
.99
76.%
32
WIDUS (3)
.89
.44
.23
.96
51%
61
WIDUS+abortion (4)a
.80
.66
.21
.97
76%
39
DAST (1)
.72
.76
.36
.94
75%
32
b
Lifetime
.69
.66
.28
.92
67%
39
CAGE (1)
.64
.75
.32
.92
73%
32
.58
.87
.46
.92
83%
20
Three monthsc
DAST (2)
.39
.90
.42
.89
82%
14
CAGE (2)
.39
.87
.36
.88
79%
17
d
Last month
.34
.99
.91
.91
91%
5
Note. Cutoff scores for the WIDUS, DAST, and CAGE are in parentheses.
a
Statistics are from the validation sample (N = 100).
b
Drug use endorsed in lifetime.
c
Drug use endorsed during the three months prior to pregnancy recognition.
d
Drug use endorsed in the last month.

Discussion
The purpose of this study was to develop an indirect screening tool to detect prenatal
drug use. The research built upon the work of Dr. Steven Ondersma and colleagues, during the
development of the Wayne Indirect Drug Use Screener (WIDUS). The current study was an
extension of this research, with a focus on detecting drug use in pregnant women. Four main
research questions: (1) Are women in this population underreporting prenatal drug use? If so,
what is the extent of the discrepancy between self- and biological-report?, (2) Do pregnancyrelated variables offer additional predictive validity to an existing indirect drug screening tool
developed with postpartum women (i.e., the WIDUS)?, (3) Considering both prenatal and
general drug use correlates, what items best predict recent drug use in this sample of pregnant
women?, and (4) How well do direct (e.g., standardized screening questions) and indirect
measures of prenatal drug use predict objective evidence of such use (i.e., positive UDS)? It was
hypothesized that women will underreport their prenatal drug use (Hypothesis 1) and that
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indirect screening tools will better identify recent drug use than direct screening measures
(Hypothesis 2).
The subsequent discussion will answer these questions by summarizing results of data
analysis. The implications of these findings, as well as directions for future research, will then be
presented. Lastly, limitations of the study will be addressed.
Research Question 1: Self-reported Drug Use versus UDS
When self-report and objective (USD) measures of prenatal drug use were compared,
prevalence rates varied, evidencing underreporting in this study. As hypothesized, participants
tested positive for recent drug use at a rate higher than they self-reported.This was true even after
certain drugs that could have been used legally (i.e., with a prescription) were excluded, lowering
the prevalence rate by biological report from 19% to 16%. Thus, even when using a conservative
rate, only one-third of participants who tested positive self-reported drug use in the past month. It
is likely that the “true” rate of prenatal drug use (i.e., use of any illicit drug during pregnancy) is
even higher and would reflect higher rates of underreporting. Nonetheless, rates of
underreporting are consistent with results from other urban, prenatal samples (Markovic et al.,
2000; Ostrea et al., 1992) and the the parent study (Grekin et al., 2010).
Research Question 2: Predictive Validity of Pregnancy Variables
The second research question- do pregnancy-related variables contribute additional
predictive validity to the original WIDUS screener- was evaluated using N = 46 pregnancyrelated items. Surprisingly, only one item retained statistical significance at the end of the item
reduction process. The abortion item added significant predictive validity above and beyond the
WIDUS. While this item added significant predictive validity, above and beyond the WIDUS,
the item focused on the controversial issue of abortion.
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While it may be surprising that only the abortion item was significantly associated with
prenatal drug status within the context of other risk factors, it is not unexpected that this item
retained significance during multivariate analyses. Several studies have documented an
association between abortion and mental health problems. However, there is discrepancy within
the literature as to how this relationship is best conceptualized. Some researchers view abortion
as a traumatic experience with negative psychological consequences (Coleman, Coyle, Shuping,
& Rue, 2009), others attribute the association between abortion and mental health problems to
common risk factors (i.e., SES, violence history, prior mental health, described in Steinberg &
Finer, 2011). In an investigation of the common-risk-factors model with a nationally
representative sample (i.e., women who responded to the abortion question as part of the
National Comorbidity Survey Part II; N = 2065), Steinberg & Finer (2011) examined the
relationship between history of abortion (0, 1, and multiple abortions) and having a substance use
disorder (according to DSM III-R criteria). After controlling for socio-demographic (e.g., race,
income, marital status) and other risk factors (e.g., intimate partner violence, age at first abortion
or pregnancy), abortion (having multiple versus zero abortions) was significantly associated with
having a current substance use disorder diagnosis (OR = 3.7, 95% CI = 1.2, 11.7). Although the
strength of this association was reduced when common risk factors were controlled for (i.e., the
OR decreased from 5.2, 95% CI = 2.2, 12.2), these findings still lend support to the current
results concerning the predictive validity of the abortion item.
Research Question 3: Predictive Validity of Indirect Items within a Pregnant Sample
Research question 3 concerns which indirect items, among both prenatal and general drug
use correlates, best predict recent drug use. Utilizing the full item pool, six indirect items were
retained during the item reduction process as a result of their univariate and multivariate
relationships with drug status. Together, these six items formed the WIDUS-Pregnancy
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(WIDUS-P). Two items, the 100 cigarettes and pain (in teeth or mouth) items, overlapped with
the WIDUS. The abortion item, retained in question 2, was also included. Overall, the measure
performed well in cross-validation analyses. The WIDUS-P showed good accuracy in
distinguishing recent drug users from non-drug users (i.e., women with no evidence of recent
prenatal drug use). Within the validation sample, it identified 90% of women who tested positive
for recent drug use and almost three-quarters of women who did not test positive. With a cut-off
score of three, the WIDUS-P correctly classified 76% of all women in the validation sample. In
addition, it accounted for significant unique variance, not captured by the WIDUS, in predicting
prenatal drug use. Data from randomly selected validation samples also support the classification
accuracy and high sensitivity of this measure.
Research Question 4: Direct versus Indirect Measures of Prenatal Drug Use
Research question 4 focused on how well the direct self-report measures of drug use
predicted prenatal drug use (i.e., positive UDS) in this sample of pregnant women. The indirect
measures, the WIDUS, WIDUS+abortion and WIDUS-P, were superior to all direct measures
and questions in terms of sensitivity. The WIDUS-P emerged as the most sensitive indirect
measure as well as the most specific. The DAST and the Drug CAGE, using the lowest possible
cut-off scores, were moderately sensitive screening tools; although, the DAST outperformed the
CAGE (.72 versus .64). Overall, the direct methods (i.e., the question about last month use, the
DAST with a cut-off score of 2, and the question about use during the 3 months prior to
pregnancy recognition) accurately classified the most participants; however they had only poor
to moderate sensitivity. For example, asking women if they used drugs in the past month
correctly identified almost 91% of participants, but missed two-thirds of drug users. Given the
study’s priority on identifying prenatal drug use, indirect measures were more successful at
identifying UDS positive cases of prenatal drug use than direct methods.
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Although, indirect methods clearly offer a predictive advantage, the utility of direct
measures may be sample dependent. Results from Grekin and colleagues (2010), utilizing data
from the parent study at Wayne State University, support a different perspective of the DAST’s
sensitivity and disclosure of drug use. In their sample of 300 women who had recently delivered
at an urban obstetric hospital in Detroit, the DAST was less accurate than in the current study in
identifying prenatal drug use. For identifying any drug use (i.e., cocaine, amphetamines, opiates
and/or marijuana), the DAST, with a cut-off of one, was less sensitive (.47 versus .72 in current
study). Rates of self-reported past year drug use, according to the DAST-10, question #1, also
differed between samples, with participants in the current sample endorsing higher rates (13%
versus 19%).
Overall, women in the present study self-reported drug use and its consequences more
freely than women in the Detroit sample. Women in this study might have felt more comfortable
disclosing for several reasons. One, they were in an outpatient setting versus a controlled
environment, where they were only interacting with staff for a specified amount of time and
could leave voluntarily. In addition, because women were still pregnant, the possible
consequences of prenatal drug use (e.g., loss of custody) were less immediate and thus women
might not have felt as vulnerable (Harris & Paltrow, 2003). Lastly, some participants were
recruited from “high-risk” clinics which included women with known medical conditions and
substance problems that complicated pregnancy. For some participants, they may have felt more
comfortable disclosing prenatal drug use because their medical providers were already aware of
this information and/or they were openly seeking treatment for drug use. Together, differences
between samples suggest that self-disclosure, and consequently, the utility of the DAST as a
screening tool for prenatal drug use, may be sample dependent.
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Implications and Future Directions
Implications of the present study’s results are discussed below within the context of 1)
the sample’s severity of biopsychosocial risk factors, 2) advances in methodological issues
related to screening for prenatal drug use and estimating rates of underreporting, and 3) indirect
measures as a promising screening approach. Directions for future research are also described.
Severity of psychosocial risk factors. While the primary focus of the present study was
measure development, study findings also point out the nature and types of psychosocial risk
factors that impact the target group of pregnant women. Self-report data confirm that many
witnessed or experienced various negative life events, including childhood physical and sexual
abuse, physical abuse as an adult, and unsafe partner relationships. For many women, drugs were
present in their childhood environments as well as during their current pregnancy. About half
the sample reported smoking cigarettes prior to becoming pregnant and a similar percentage
reported that the father of their fetus was a current smoker. Many women also had close friends
who used marijuana. These data affirm the need for better screening and intervention programs
focused not only on substance use but also other areas of risk.
As a whole, current study participants were predominantly young, low-income, minority
women and many noted this was not their first pregnancy. Health disparities research has found
infant mortality and morbidity rate differences continue to be an area of much concern.
Specifically, NCHS found the death rate for African American infants (13.3/1,000 live births)
was two times higher than the national average of 5.6/1,000 live births (NCHS, 2011). Central to
the problem of infant mortality is preterm birth (MacDorman, Callaghan, Mathews, Hoyert, &
Kochanek, 2007), with African Americans accounting for the highest percentage of cases (17.8%
versus 11.5% for Whites; Behrman & Stith-Butler, 2006). One important risk factor for such
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outcomes is prenatal substance use. Clearly, the present sample of women is at increased risk for
having a preterm birth or other maternal or infant complications.
It is important to recognize that the risks for adverse pregnancy-related outcomes are not
limited to those women who screened positive for prenatal drug use by UDS or self-report. Many
of the larger pool of women (84%) did not screen positive for prenatal drug use, but nonetheless
remain at increased risk for poorer outcomes due to a variety of factors. First, it is likely that
some women were still missed with the more intensive screening procedures used in the present
study. Urine drug assays have a limited window of detection (i.e., up to 2-3 weeks for regular
marijuana use) and thus can only identify more recent use so the prevalence of any drug during
pregnancy is likely to be higher. Other women used pre-pregnancy but then stopped. Many will
return to use post-partum (Ebrahim & Gfroerer, 2003). A significant proportion of study
participants reported current symptoms of depression or anxiety (about half reported “feeling
down, depressed or hopeless,” and being “easily upset”). Difficulty controlling anger was
another common problem, with 52% of women noting they “get easily and [feel] a need to blow
off some steam.” Current health and economic stressors (e.g., ER visits, poor nutrition,
transportation issues, housing instability) were also quite common. Collectively, this
information suggests that in addition to interventions for prenatal drug use, there is a need for
multi-faceted prevention and intervention efforts to promote general health and well-being in this
at risk population of women and their children.
Advances in methodological practices. During development and validation of an
indirect drug use screener in the target population of low-income, minority women, several
methodological considerations were given careful thought and consideration. First, specific
steps were taken to create an environment that assured patients of anonymity and confidentiality.
For example, self-report surveys were administered using ACASI technology. Such practices
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tend to promote disclosure of sensitive behaviors (Durant et al., 2002; Newman et al., 2002).
Second, the present project was one of the few that compared self-report screeners to a biological
measure of drug use (i.e., urinalysis). While urine drug screening is not without limitations,
particularly for substances with a short half-life, it nonetheless provides a more objective
measure of recent substance use, thereby minimizing effect of underreporting on rates of prenatal
drug use. Consequently, study findings offer new information about the sensitivity and
specificity of two commonly-used screening tools for predicting prenatal drug use (DAST and
Drug CAGE). Results yielded only moderate sensitivity for both screeners, suggesting many atrisk women would have fallen through the cracks if screening was limited to such tools.
Despite practices to facilitate self-reported drug use, pregnant women in this sample still
underreported their drug use (69% tested positive by UDS, but denied past month use). Results
suggest that under the best of circumstances, every two out of three women who screened
positive by UDS would not, in clinical practice, come to attention of their healthcare providers
via current screening practices (i.e., direct self-report). This finding is consistent with the results
of Grekin and colleagues (2010), who found that 80% of the sample who had a positive urine
and/or hair screen denied drug use. In comparing these two studies, there is also evidence to
support some differences in the degree of disclosure of drug use and related consequences
between these two samples (i.e., differences in endorsement rates of DAST items, greater legal
consequences associated with testing positive postpartum versus testing positive prenatally in an
outpatient setting). Regardless, screening efforts that rely solely on self-report to identify
prenatal drug use are likely to miss a significant proportion of drug users even when ideal
conditions for disclosure are present. Not surprisingly given underreporting, indirect screening
measures emerged as the best approach to identify recent prenatal drug use.
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The merit of indirect screening. The WIDUS, WIDUS+abortion and WIDUS-P were
the most sensitive screening tools, identifying the greatest proportion of drug users. While
additional research is needed to further examine the predictive validity of these different
screeners, collectively, these findings provide a promising start to better identification of prenatal
drug use. Interestingly, the WIDUS, which was developed and validated on postpartum women
in Detroit, performed well in identifying pregnant drug users in this sample. This supports
generalizability of the WIDUS from postpartum women to other samples of urban pregnant
women. Additionally, the results of this study suggest that adding the abortion item may increase
the predictive validity of the WIDUS. Although this improvement may be small, it may lead to
better identification of prenatal drug use across time. An important consideration to adding this
item is that women may feel uncomfortable answering this question. While the item is indirect
(i.e., it does not reference drugs) and may add unique variance, it may threaten the innocuous
intention of an indirect measure. Conversely, pregnant women may not view this question as
offensive because it is asked within an OB setting where questions about their reproductive
health are appropriate and expected. Future studies are needed to support the incremental validity
of the abortion item to the WIDUS and also to determine OB patients’ acceptability of including
the abortion item in a brief measure.
The WIDUS-P, developed and validated on this sample was the most sensitive measure
of prenatal drug use. While the WIDUS-P performed well as a prenatal drug use screener in this
sample, it is important to take into consideration the generalizability of this measure given the
shape of its ROC curve. For the ROC curves of both the training and validation samples, changes
in cut-off scores at certain levels were associated with dramatic changes in sensitivity and
specificity. For example, within the validation sample, sensitivity decreased from .90 to .50 when
the cut-off score was increased from three to four. In this sample, the optimal cut-off score was
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three. A higher cut-off score results in a significant compromise in sensitivity. However, given
that cut-off scores are very sample dependent, these drastic changes in sensitivity and specificity
could be problematic when the WIDUS-P is used in different samples. The WIDUS-P may not
be as useful for identifying prenatal drug use when applied to different samples of pregnant
women (e.g., private practice settings, rural OB clinics).
Clearly, further research is needed to evaluate the predictive validity of each of these
three measures. At present, there is too much variability to make definitive statements across
studies and measures. Next steps include evaluating these measures in different samples of
pregnant women (e.g., women who have recently delivered at VCU, other urban OB clinics),
extending the window of drug detection by including hair analysis, and utilizing different
statistical techniques in both the development (i.e., item reduction process) and validation phase
of measure development. In this study, we chose to develop the WIDUS-P on a sample of 131
participants and then validate it on the remaining 100 participants. An alternative approach
would have been to use CART or LOO (leave one out) cross-validation. Different statistical
processes may identify additional items that contribute unique variance not captured in the
WIDUS-P items. Similarly, they may also confirm the predictive validity of the WIDUS-P items.
Further investigation of indirect screening, based on the present findings, could also be
extended to examine the combination of direct and indirect screening. Asking participants
directly about their drug use in the past month had high specificity, but low sensitivity. On the
other hand, the WIDUS-P had high sensitivity and lower specificity. Combining these
approaches could lead to an ideal combination of sensitivity and specificity. Concurrent
screening (i.e., in a single measure, asking the WIDUS-P items first and then question about past
month use) is preferable to sequential screening (i.e., administering the WIDUS-P only if past
month drug use is denied) because women could become defensive when asked directly about
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recent drug use and consequently, minimize subsequent report of any behaviors or life
experiences.
Indirect screening is a stark contrast to current screening approaches which are either
non-existent or involve direct mention of drug use and its consequences. Compared to these
methods, an indirect approach offers more effective screening. As supported by the present
findings, indirect tools are more sensitive measures of prenatal drug use than direct methods:
they identify a greater proportion of recent drug users. This is of paramount importance because
in order for prenatal interventions to be effective, screening tools must first accurately identify
at-risk women. From a public health perspective, if a significant proportion of women who use
drugs prenatally are missed, the intervention has less of an impact at the population level.
Interventions are also less effective when they are not easily applied to real world settings
(Smeeth & Ebrahim, 2000). The innocuous nature of indirect screening enables this approach to
be easily implemented into regular clinic practice. OB clinic staff will likely be more receptive to
using a screener which does not directly address drug use than using a face-valid screener such
as the DAST or Drug CAGE. Additionally, a computerized screening tool offers both time and
cost savings for providers, as well as greater translational value, as it can be easily integrated into
standard care in a variety of health settings. Taken together, an indirect, computerized screener,
such as the ones reported in this study, can allow practitioners to screen more pregnant women
and better identify those at risk for drug use.
Limitations
One of the main limitations of this study was the way in which participants’ drug status
was defined. Pregnant women were considered “drug positive” if their urine drug screen was
positive for methamphetamines, cocaine, marijuana, barbiturates, MDMA and/or PCP. Thus,
biological report was based solely on UDS and not both hair and urine testing, as was collected
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in Dr. Ondersma’s research. This method of biological testing was chosen for several reasons.
Urine samples are relatively easy to collect as OB clinic patients are accustomed to providing
them as part of their routine prenatal care and this method is less invasive than collecting hair or
blood samples. In addition, urinalysis costs less than other methods (e.g., hair analysis costs
around $75/sample). Furthermore, despite urinalysis’ short window of detection for most drugs,
this method is appropriate because one of the most common drugs of abuse among this
population is marijuana (Saitz, Svikis, et al., 2006), which has a much longer window of
detection than other drugs (Wolff et al., 1999). Finally, given that the prenatal clinic does not
ever screen for illicit drugs and that all study information was collected anonymously,
contamination of urine samples by participants was considered unlikely because there was no
specific motivation for women to reduce or eliminate use prior to their prenatal visit. Although
both urine and hair assay were utilized in Dr. Ondersma’s study with postpartum women, for the
aforementioned reasons, urinalysis was selected for use in the current study.
As a result of using only urinalysis as the gold standard criterion, the window of detection
in this study was shorter than if both methods had been utilized (i.e., the full period of pregnancy
was not captured by toxicology screens). Consequently, women who used drugs during
pregnancy but outside of the window of detection for urinalysis were “missed.” For example, a
participant in her third trimester could have used marijuana during her first trimester but not have
tested positive on the UDS. Additionally, because it was unknown whether women were using
benzodiazepines, methadone, opiates and/or oxycodone legally (i.e., with a prescription), this
data was omitted from their drug status. Participants’ medical records could not be accessed to
rule-out prenatal prescription drug use because the study was anonymous. In this manner,
anonymity was both a strength and limitation of the study. Given these limitations, it is likely
that the “true” rate of prenatal drug use is even higher than the rate documented (15.6%). It is
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possible that this underestimation of drug use affected which indirect items were selected and the
predictive validity of the various direct and indirect screening methods examined.
Another limitation concerns the issue of generalizability. The study was conducted with
pregnant women who were predominately African American, low-income, and young. From a
health disparities perspective, this is an important at-risk group to study; however, results may
not generalize well to other populations. In addition, the primary drug used by women who
tested positive was marijuana. Thus, it is unknown how well the predictive validity of indirect
screeners developed in this study will apply to other classes of drugs.
Final Thoughts
Current prenatal drug use screening practices are insufficient. Indirect screening is a
promising approach to better identify drug use in pregnant women, regardless of their
willingness to disclose such use. Although changes to prenatal drug use screening addresses only
one part of a complex problem, it is an important foundation upon which to impact greater
numbers of at-risk women and build more effective interventions.
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Appendix 1
Preliminary Literature Review of Correlates of Current Drug Use: Behavioral, Medical,
Psychological, Experiential, and Demographic
Borrowed from Dr. Steven Ondersma
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Suicide attempt
Associating with drug-using
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Problem alcohol use
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Lifetime drug use
Impaired occupational
functioning
Impaired academic
functioning
Impaired social functioning
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Schafer, Schnack, & Soyka, 2000)
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1990)
(Cohen & Densen-Gerber, 1982; Goldstein et al., 1996)
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(Boyd, 1998; Schafer, Schnack, & Soyka, 2000)
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(Buelow & Buelow, 1995)
(Larsson, Eriksson, Zetterstrom, 1979; Stein, Newcomb, &
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Glavak, Kuterovac-Jagodic, & Sakoman, 2003; McCuller et
al., 2001; Newcomb, 1997; Yeh, Chen, & Sim, 1995)
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1996; Morey & Friedman, 1993)
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Appendix B
Recruitment Script

Part A.
“Hello, my name is ________ and I am part of the AWHARE Women’s Health Research team
here at VCU. We are conducting a project with pregnant women at Nelson Clinic. May I talk to
you for a few minutes?”
“First, can I ask if you are at least 18 years old?”
IF “NO”: “Thank you for your time. At this point, you do not qualify for this study.”
“And, may I ask if you are here today for a RETURN prenatal appointment?”
IF “NO”: “Thank you for your time. At this point, you do not qualify for this study.”
“I am working on a research project that focuses on developing a questionnaire that will help
identify women who may need help. The project is ANONYMOUS- it will not require you to tell
me your name. It involves a questionnaire that will ask you about your health, activities and
habits, childhood and teenage experiences, life experiences, thoughts, and feelings. It will take
about 30 minutes to complete after your OB appointment today and you will be given up to $40
in gift cards for your time.”
“Are you interested in participating today?”
IF “YES”: “Ok, well I will wait for you in the waiting room until you finish your
appointment. Afterwards, we can go to our research offices across from Ultrasound and I
can tell you more about the project and then you can complete the study if you are
interested. Here is a reminder card for the study.”
RA will give the woman a reminder card.
After patient’s appointment, RA will take her to office space, collect the reminder card, and read
Information Sheet #1 to the patient.
Complete Phase 1.
Part B.
RA will give participant her gift card and then read Information Sheet #2.
“Are you interested in participating in Phase 2?”
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IF “YES”: “Ok, I will show you where the restroom is. Once you are inside the restroom,
you’ll see a metal cabinet. Inside the cabinet is a urine sample cup. Please fill the cup
about 1.5 inches full of urine and then place it back in the cabinet when you are done. I’ll
be waiting out here after you have finished.”
Complete Phase 2: RA shows the patient to the restroom. After the patient has provided a sample
and left the restroom, the RA will give her Information Sheet #3, give her a gift card, and thank
her for her participation.
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Appendix C
WIDUS-P Development Version

“Basic Information About Me.”
Here are some questions about you...your living, and work
situation right now...Okay, here we go...
1. How old are you?

a) 18-21
b) 22-25
c) 26-29
d) 30-33
e) 34-37
f) ≥ 38

2. What is your ethnic background?

3.

a) American Indian or
Alaska Native
b) Black or African
American
c) Hispanic or Latino
d) Native Hawaiian or
other Pacific Islander
e) Asian
f) White
g) Middle Eastern
American (Assyrian,
Lebanese, Kurdish, Arab,
Aremaic, etc)
h) More than one race
i) Unknown

I am currently married. (5)

True

False

4. I graduated from high school or completed my GED. (6)

True

False

5. I am currently working 20 hours or more per week. (7-edited)

True

False

6. I currently have health insurance through an employer, either mine

True

False
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or a family member’s (do not include Virginia Premier). (8 edited)
7.

I currently receive some form of public assistance, such as food
stamps, WIC, Medicaid, SSI, or TANF. (9)
“My Health.”
Here are some True and False questions about your health...
8. At least once in my life, I have been diagnosed with a sexually
transmitted disease, such as gonorrhea, Chlamydia, Herpes,
syphilis, HIV, or any other sexually transmitted infection. (12)
9. I have been diagnosed with Hepatitis C. (13)

True

False

True

False

True

False

10. I almost always use condoms during sex. (14)

True

False

11. I often eat fast food and/or junk food. (15)

True

False

12. I have been treated at an emergency room in the past year. (16)

True

False

13. I have missing teeth. (17)

True

False

14. In the past year, I have been bothered by pain in my teeth or mouth.
(18)
“My Activities and Habits.”
We’d like to know just a little about what you do, and some of your
habits... We ask everybody the same questions...you may or
may not do these things... Remember, no one will know your
answer...
15. I have smoked at least 100 cigarettes in my entire life. (19)

True

False

True

False

16. I was a daily smoker during the year before I became pregnant. (20)

True

False

17. I smoked at least one cigarette the week before I learned I was
pregnant. (21-revised)
18. I’m often around second hand cigarette smoke. (25)

True

False

True

False

19. Most of my friends smoke cigarettes. (26)

True

False

20. At least two of my closest friends use marijuana. (27)

True

False

21. Most of my friends think marijuana is no big deal. (29)

True

False

22. I have at least one caffeinated beverage (for example, caffeinated
soda, coffee, or energy drink) every day. (31-revised)

True

False

True

False

True

False

“My Childhood and Teenage Experiences.”
We’d like to ask you about some things that you, may or may
not have experienced in your childhood and teenage
years...you may or may not have seen similar questions
before, but they are different because we are asking about
your childhood or teenage years... Please answer True or
False on each statement...let's go...
23. When I was a child, I saw adults in my home physically hurting
each other. (34)
24. When I was a child, I saw someone get stabbed, shot, or seriously
beaten. (35)
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25. When I was a child, an adult hit me hard enough to cause bleeding,
bruises, or welts. (36)
26. When I was a child, an adult touched my private parts in a sexual
manner, or got me to touch their private parts in a sexual manner.
(37)
27. When I was a child, I saw people using drugs in my home. (40)

True

False

True

False

True

False

28. Since my sixteenth birthday, I have had fractures or dislocations to
my bones or joints. (42)
29. Since my sixteenth birthday, I have injured my head. (44)

True

False

True

False

30. Since my sixteenth birthday, I have been injured in an assault or
fight (not counting injuries during sports). (45)

True

False

31. There have been times in my life, for at least two weeks straight,
where I felt completely worthless. (47)
32. There have been times in my life, for at least two weeks straight,
where I felt completely hopeless about things. (48)
33. There have been times in my life, for at least two weeks straight,
where I felt so down or depressed that nothing could cheer me up.
(49)
34. There have been times in my life, for at least two weeks straight,
where it felt like everything was an effort. (50)
35. As an adult, I have been badly beaten up at least once. (53)

True

False

True

False

True

False

True

False

True

False

36. As an adult, I have seen somebody get stabbed, shot, or seriously
beaten. (54)
37. One or more of my biological parents have had a problem with
drugs or alcohol. (56)
38. One or more of brothers or sisters has had a problem with drugs or
alcohol. (57)
39. I have been abandoned by someone I love more than most people
have. (60)
40. I have been in trouble with the police. (61)

True

False

True

False

True

False

True

False

True

False

41. In my lifetime, I have been hit, slapped, kicked or otherwise
physically hurt by someone.
42. There have been times in my life I have not felt safe around my
current partner or past partner.

True

False

True

False

“My Lifetime Experiences.”
We'd like to ask you about some things that you may or may
not have experienced in your lifetime...you may or may not
have seen similar questions before, but they are different
because we are asking about your whole life. Please answer
True or False on each statement...
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“My Recent Experiences.”
We'd like to ask you about some things that you may or may
not have experienced recently...you may or may not have seen
similar questions before, but they are different because we
are asking ONLY about recent experiences. Please answer
True or False on each statement...
43. Within the last year, I have been hit, slapped, kicked or otherwise
physically hurt by someone.
44. During my current pregnancy, I have been hit, slapped, kicked, or
otherwise physically hurt by someone
45. In the past year, I’ve gone hungry because I didn’t have enough
money to buy food.
46. It’s hard to get places because of transportation.

True

False

True

False

True

False

True

False

47. In the past 12 months, I’ve worried about my housing situation.

True

False

48. I often move from place to place.

True

False

49. In the past year, the police have been called to my home because of
a fight or argument. (67)
50. Things have usually gone against me in life. (69)

True

False

True

False

51. I get mad easily and feel a need to blow off some steam. (70)

True

False

52. Some of my immediate family members are pretty violent. (71)

True

False

53. I feel overwhelmed by my life and my problems. (75)

True

False

54. I get bored easily. (79)

True

False

55. I live life on the edge. (80)

True

False

56. I have conflict with people in authority, like teachers, supervisors,
and the police. (81)
57. I experience “flashbacks” of bad things that have happened to me.
(82)
58. At least one person in my immediate family (parent, brother, or
sister) has had problems with depression. (83)
59. I sometimes do really harmful things to myself. (84)

True

False

True

False

True

False

True

False

60. In elementary school, I often got into trouble with teachers or the
principal because of my behavior (fighting, talking in class, or
coming to class late). (85)

True

False

“My Personality, Attitudes, and Feelings.”
We would like to ask you some True or False questions about
you, your personality, attitudes, and feelings...everybody's
answers are different... Some questions may or may not make
you feel uncomfortable...so, do your best to answer the
questions... Remember that nobody will know your answers...
This section is the longest one, it should take about 5 minutes.
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61. I am easily upset about things. (86)

True

False

62. When I was younger than 13 years old, I often stayed out past
midnight. (87)
63. I have seen or experienced worse things than most other people
have. (90)
64. Over the past month, I have felt down, depressed, or hopeless. (91)

True

False

True

False

True

False

65. Drugs are everywhere in my neighborhood. (94)

True

False

66. I often have trouble sleeping (not counting during pregnancy). (95)

True

False

67. I feel very overwhelmed when thinking about taking care of a new
baby. (96)
68. I have repeated and disturbing memories of a stressful thing that
happened to me. (99)
69. I lose my temper very easily. (100)

True

False

True

False

True

False

70. In the past, I have told someone that I was going to hurt myself.
(105)
71. I often feel empty inside. (108)

True

False

True

False

72. In the past, I have attempted to hurt myself. (114)

True

False

“My current pregnancy”
So, now we’d like to ask you some questions related to your
pregnancy.
73. How many weeks pregnant are you?

1-42

74. How many weeks pregnant were you when you first thought you
might be pregnant?
75. How many weeks pregnant were you when attended your 1st OB
appointment.
76. Thinking back to just before you got pregnant, how did you feel
about becoming pregnant?

1-42

77. How many times have you been pregnant, including the current
pregnancy?
78. How many of these pregnancies ended in the birth of a live baby?
79. Have you ever had a baby that died during birth or was stillborn?
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1-42
a) I wanted to be pregnant
sooner.
b) I wanted to be pregnant
then.
c) I wanted to be pregnant
later.
d) I didn’t want to be
pregnant then or at any
time in the future.
e) I don’t know.
This is my first
pregnancy, 1,2,3,4,5, 6, 7,
8 or more
None, 1,2,3,4,5, 6, 7, 8 or
more
Yes

No

80. Have you ever had a pregnancy that ended during the first 4
months (not including an abortion)?
81. Have you ever had a pregnancy that ended after 4 months but
before birth?
82. Have you ever had an abortion?
83. Are you currently in a relationship?

Yes

No

Yes

No

Yes

No

a) Yes, with the father of
my baby.
b) Yes, with someone
other than the father of my
baby.
c) No, I am not in a
relationship.

“The father of this baby”
We’d like to know just a little about your relationship with
the father of your baby and some of his habits... We ask
everybody the same questions...you may or may not do these
things... Remember, no one will know your answer...
84. Thinking about the amount of contact you’ve had with the father of
this baby, which statement best fits you?

a) I’ve had contact with
the father of this baby in
the past and right now.
b) I’ve had contact with
the father of this baby in
the past but not right now.
c) I don’t know the father
of this baby that well.

85. The father of this baby currently smokes cigarettes.

True

False

86. The father of my baby thinks marijuana is no big deal.

True

False
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Appendix D
Information Sheet #1

ANONYMOUS SURVEY
Consent Information Sheet
Are you pregnant?
Part One
 We would like your help in developing a questionnaire that will help identify women
who may need help. This survey is for pregnant women who are 18 years of age and
older and who are coming to Nelson Clinic for prenatal care.


If you choose to participate, we’ll ask you to complete a questionnaire on the computer
while you wait to be called back for your appointment. This survey will take about 20
minutes and will ask you about many different things about yourself, including your
background information, health, activities and habits, childhood and teenage experiences,
lifetime experiences, personality, attitudes, thoughts, and feelings.



There are very few risks to you for participating. You may find some questions easy to
answer and others may be harder to answer. Please be as honest as possible. If you get
uncomfortable and don’t want to answer a question, that is ok. If you start the survey and
don’t want to finish that is ok too.



This questionnaire is ANONYMOUS, meaning we are not asking you for your name so
we won’t be connecting your name with your answers.



Your participation is VOLUNTARY and whether you choose to participate or not will
not affect your care at Nelson Clinic.



For completing the survey, we will give you a $20 gift certificate.

Part Two: We’ll tell you more about part two after you have completed Part One.
This project is a VCU-sponsored research project. If you have any questions about the project,
please call Courtney Smith at (804)-628-2553 or Dr. Svikis at (804)-827-1184. Thank you for
your help! We appreciate your input and feedback.
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If you have any questions about your rights as a participant in this study, you may contact: Office
for Research, Virginia Commonwealth University, 800 E. Leigh Street, Suite 113, P.O. Box
980568, Richmond, VA, 23298. Telephone: 804-827-2157.
***OPTIONAL: You can sign this consent form if you want to do so. Your signature is not
required to participate in the study.
CONSENT
I have been given the chance to read this consent form. I understand the information about this
study. Questions that I wanted to ask about the study have been answered. My signature says that
I am willing to participate in this study.

Participant name print

Participant signature

Date

Witness name printed

Witness signature

Date

Name of person conducting
Informed Consent printed

Signature

Date

Investigator signature (if different from above)

Information Sheet #1
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Appendix E
Information Sheet #2

Thank you for participating in Part One! Now, we’ll tell you about Part Two.
Part Two: The second part of this project asks for your verbal permission to drug test your
urine. If you agree to participate, the staff member will perform the test after you provide a
sample for the study. They will test your urine in the bathroom without any clinic staff, doctors,
or nurses present. After the testing is complete, they will immediately discard the results. Your
results will not have your name on it and will NOT be shared with any staff, doctors, or nurses at
Nelson Clinic. For your participation, you will be given a $20 gift card. Just like Part One, your
participation is voluntary and will not affect your care at VCUHS.
This project is a VCU-sponsored research project. If you have any questions about the project,
please call Courtney Smith at (804)-628-2553 or Dr. Svikis at (804)-827-1184. Thank you for
your help! We appreciate your input and feedback.
***OPTIONAL: You can sign this consent form if you want to do so. Your signature is not
required to participate in the study.
CONSENT
I have been given the chance to read this consent form. I understand the information about this
study. Questions that I wanted to ask about the study have been answered. My signature says that
I am willing to participate in this study.

Participant name print

Participant signature

Date

Witness name printed

Witness signature

Date

Name of person conducting
Informed Consent printed

Signature

Date

Investigator signature (if different from above)
Information Sheet #2
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Appendix F
Information Sheet #3

Thank you for participating in both Part One and Two of this project. Your help is greatly
appreciated. We asked you about Part Two after you completed Part One because we wanted you
to answer the questions as any pregnant woman attending prenatal care would do. That is, we did
not want to influence your responses to Part 1. If you have any questions about the project,
please call Courtney Smith at (804)-628-2553 or Dr. Svikis at (804)-827-1184. Again, thank you
for your time!

Information Sheet #3
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